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ABSTRACT 
 
Over the past few decades, our knowledge of tumor immunology and the role antitumor 
immune responses play in tumor recognition and eradication has greatly increased and led to 
immunotherapies being investigated as a promising strategy for cancer treatment. Current 
clinical studies with various immunotherapies have shown promising results, including therapy 
with adoptive cell transfer (ACT) of T lymphocytes. T cell immunotherapy is highly attractive 
because T cells have the ability to selectively recognize and destroy malignant neoplastic cells. 
Although a promising approach, one of the limitations encountered clinically is the difficulty 
isolating and expanding tumor-specific T lymphocytes from patients. This limitation may be 
circumvented by genetically engineering T lymphocytes to express antigen-specific T cell 
receptors (TCR). The goal of this work was to investigate adoptive T cell therapy using primary 
T lymphocytes modified to express genetically engineered T cell receptors against murine 
melanoma and glioma. 
In chapter 2, a new SIYRYYGL (SIY) peptide-expressing murine glioma cell line 
(GL261-SIY) was generated as a model to investigate strategies to improve adoptive T cell 
therapy for brain tumors. Our findings demonstrated successful development of this new cell line 
as determined by surface expression of SIY antigen and effective peptide presentation to T cells 
in vitro resulting in T cell activation and induction of cytotoxic T cell activity. In vivo, T cell 
infiltration of brain tumors and long-term survival benefits with adoptive transfer of transgenic 
and TCR-modified T cells was examined.  
In chapter 3, ACT of MHC class I-redirected CD4
+
 helper T cells was evaluated in a 
subcutaneous murine melanoma tumor model. TCRs specific for MHC class I-restricted antigens 
were introduced into CD4
+
 cells to assess whether high affinity TCRs, in the nanomolar affinity 
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range, could provide an enhanced antitumor response compared to micromolar affinity wild type 
TCRs. Our study revealed improved survival and long-term immunity with CD4
+
 T cells 
expressing high affinity MHC class I-restricted TCRs. 
T cell therapy with CD4
+
 T cells (alone or in combination with CD8
+
 T cells) for the 
treatment of murine glioma and melanoma resulted in development of graft-versus-host disease 
(GVHD) in some mice. In chapter 4, mice affected by GVHD were studied in detail. Clinical 
signs, physical GVHD presentation, and GVHD-associated histopathology were dissected to 
better understand the mechanisms and factors involved in the in vivo interactions between the 
transferred T cell populations and the affected host tissue.  
 Overall, this work examined adoptive therapy with ex vivo activated T cells expressing 
wild type or high affinity genetically engineered TCRs for the treatment of established tumors in 
mice, as well as GVHD development secondary to T cell therapy. The findings in these 
collective studies demonstrate that immunotherapy with CD8
+
 and CD4
+
 T cells expressing 
gene-modified TCRs is a distinct strategy to optimally exploit cytotoxic T lymphocyte (CTL) 
effector functions and helper T cell functions. T cell immunotherapy is a very powerful 
therapeutic approach for treatment of cancer with the potential of driving potent antitumor 
responses capable of achieving life-changing clinical benefits for patients.   
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CHAPTER ONE: 
 
INTRODUCTION 
 
1.1 General Overview of the Immune System 
 
 The immune system is comprised of two components that recognize pathogens and 
protect against infection. The innate component is the first line of defense, it is non-specific and 
recognizes pathogens in a generic manner, and is constitutively prepared to respond against 
pathogens prior to onset of infection. The adaptive component is highly specific, requires a 
longer period of time to be fully effective, and can elicit long-lasting protective immunity. 
 
Innate Immunity 
 The innate immune system provides a constitutive antimicrobial defense with the ability 
to counterattack infection rapidly. Successful protection against microbial invasion is facilitated 
by physical anatomical barriers, soluble molecules, membrane-associated receptors, and innate 
effector cells. External physiological barriers consist of skin and epithelial tissue to prevent 
microbial entry to the body. Skin and epithelial layers not only provide a physical barrier against 
microbial colonization but also produce a variety of antimicrobial agents. Antimicrobial peptides 
on the skin, digestive enzymes in the mouth and gastrointestinal tract, and cilia lining mucosal 
membranes are a few examples of the mechanisms utilized by the innate immune system to 
respond to pathogens [1].  
 Pathogens can evolve mechanisms to breach these protective barriers. Detection of such 
invaders involves pattern recognition receptors (PRRs) expressed on innate immune cells, which 
bind to and recognize pathogen-associated conserved molecular motifs (e.g. bacterial 
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lipopolysaccharide) [2]. Once detected, microbial invasion is controlled by various molecules 
and cells. Recognition of pathogen-associated patterns triggers an inflammatory response 
resulting in secretion of a cascade of cytokines and chemokines. Cytokines and chemokines are 
soluble molecules secreted by immune cells to stimulate or modify the behavior of target cells 
[2,3]. Generation of inflammatory factors leads to recruitment of phagocytic cells to the site of 
infection and promotes phagocytosis and killing of the infecting microorganisms.  
 A variety of soluble and membrane-bound receptors have been identified as important 
components for initiation of an innate immune response. C-reactive protein and mannose-binding 
lectin are two examples of soluble molecules that contribute to an inflammatory response 
through complement activation and pathogen opsonization following stimulation by microbial 
cell wall components [4-6]. Toll-like receptors (TLRs) are a family of cell surface proteins 
characterized by their role in detecting conserved microbial products and are essential in 
generating effective innate immune responses. This family of receptors (TLR1-TLR11) shares a 
common structure composed of an extracellular domain featuring leucine-rich repeats and an 
intracellular Toll/IL-1 receptor domain [7-9]. Shared signaling pathways among the TLRs induce 
key genes in host defense through activation of NF-κB and MAP (mitogen activated protein) 
kinases. 
 Specialized innate immune cells execute direct assaults on invading pathogens and 
provide essential activating signals to successfully eliminate infectious agents. The major cell 
types involved in innate immune response are natural killer cells, dendritic cells, macrophages, 
and neutrophils [10-14]. Their roles include internalize infectious agents, process and present 
microbial products on Major Histocompatibility Complex (MHC) molecules, secrete 
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proinflammatory cytokines and chemokines, as well as mobilize and direct adaptive immune 
responses against microbes.  
 
Adaptive Immunity 
 Innate immune cells communicate with adaptive immune effector cells to establish a 
cooperative connection between the innate and adaptive immune systems. Adaptive immunity is 
a highly specific, inducible defense against invading pathogens. Unlike the innate immune 
system, immunological responses following detection of microbes requires days or weeks but 
has the advantage of inducing long-lasting immune memory and thus allowing for a faster 
response during subsequent infections. Lymphocytes and antigen presenting cells are the two 
major cell types that mediate adaptive immunity.  
 Antigen presenting cells (APCs), such as dendritic cells, play dual roles as effector cells 
in both innate and adaptive immunity [10,14,15]. They display innate immune attributes and can 
be found at first line of defense areas such as the skin and gastrointestinal tract, yet have the 
capacity to stimulate lymphocytic cells and elicit adaptive immune responses. The main 
mediators of adaptive immunity are B lymphocytes (B cells) and T lymphocytes (T cells) [1,16]. 
B cells derived their name from their source of origin in birds, the ‘Bursa of Fabricious’. They 
mature in the bone marrow and are distinguished by the production of membrane-bound 
immunoglobulin receptors, or antibodies. These receptors can interact directly with molecules 
that evoke the production of specific immune responses, also known as antigens. When naïve 
antibodies bind antigens, it triggers proliferation and differentiation of B cells into plasma cells 
which secrete soluble antibodies [17]. Sequentially, soluble antibodies recognize and bind 
antigens, coating the microbe and facilitating its elimination. B cells are responsible in mediating 
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humoral immunity and somatic mutation, as well as random rearrangement of antibody encoding 
genes, regulates the antibodies diverse antigen specificity. 
 T cells migrate from the bone marrow to the thymus for maturation. The two main T cell 
populations are cytotoxic T lymphocytes (CTL) and helper T lymphocytes, which can be 
distinguished by the expression of membrane glycoproteins (CD8 or CD4) on their cell surface 
[18]. Unlike antibodies, T cell receptors (TCRs) are membrane-bound and recognize antigen 
presented on MHC molecules (class I or class II) [19]. Antigen presentation is performed via 
MHC class II molecules present on antigen presenting cells or MHC class I molecules found in 
all nucleated cells. Helper T cells express CD4 coreceptors and recognize antigen presented on 
MHC class II. Once activated, CD4
+
 helper T cells secrete cytokines important for modulating B 
cells, CTLs and antigen presenting cells’ immune responses. CTLs express CD8 coreceptors and 
bind to antigen presented on MHC class I. As their name implies, they have cytotoxic 
capabilities and play a role in surveying for and eliminating foreign, infected or altered self-cells 
(e.g. malignant cancer cells). T cell responses are restricted by binding of TCRs with antigen 
presented on MHC molecules. TCRs are heterodimers composed of two chains: either αβ or γδ 
[20,21]. Each chain has a variable domain and a constant domain linked with each other by a 
disulfide bond. For effective cell surface expression and signaling, the TCR heterodimers 
associate with CD3 polypeptide complex which contain cytoplasmic domains necessary for 
functional signal transduction [22]. Each receptor’s antigen-specificity is generated through gene 
rearrangements during the T cell maturation process. The random arrangements of TCR 
encoding genes is key for producing unique and diverse TCRs capable of recognizing billions of 
different antigens.  
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 Although highly specific and selective in its responses to foreign or altered cells, the 
adaptive immune system can malfunction and cause inappropriate immune responses. This type 
of reaction is evident in patients following organ transplant where the immune system identifies 
the transplanted organ or cells as foreign and generates an immune response against it resulting 
in graft-versus-host-disease (GVHD) [23,24]. Dysfunctional immune responses also occur when 
the immune system mistakenly recognizes self-tissue as non-self, leading to autoimmune 
disorders [25-27]. 
 
1.2 Cancer Immunotherapies 
 
 The immune system plays a vital role in surveying for and specifically destroying 
malignant cells. Cancer immunotherapies attempt to harness this protective role and stimulate 
strong immunological responses against cancer [28-31]. Supporting evidence of the immune 
system’s involvement in tumor control was partly demonstrated in immune-deficient mice which 
had a greater propensity for developing tumors. Likewise, immunosuppressed patients have a 
higher cancer incidence possibly attributed to inhibition of tumor-specific immune responses 
essential for arresting tumor growth. More recently, clinical assessment of antitumor immune 
responses in cancer patients unequivocally demonstrates participation of the immune system. 
Furthermore, these immunological responses are positively correlated with a good prognosis and, 
in some cases, with improved survival. 
Progress in our understanding of tumor immunology has led to development of new 
immunotherapy strategies resulting in successful cancer regression in clinical studies. 
Immunotherapies involving cancer vaccines, administration of tumor targeting antibodies, and 
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adoptive transfer of tumor-specific cells have advanced from the pre-clinical setting to human 
clinical studies. All of these strategies have been investigated clinically, with several of this 
strategies improving and becoming an integral part of standard treatment for various neoplasms.   
 
Cancer vaccines 
 Cancer vaccines are available in different formats: protein and peptide-based, whole cell-
based, and DNA vaccines. In general, vaccines are available for prophylactic (preventative) 
treatment or for therapeutic use. Viral origin cancers are currently being prevented with vaccines 
which protect against the viral agent. Recently, two vaccines (Gardasil and Cervarix) against 
human papilloma virus type 16 and type 18 were approved by the Food and Drug Administration 
(FDA) to prevent development of cervical cancer, vaginal cancer, anal cancer, and vulvar cancer 
[32-34]. Therapeutic cancer vaccine approaches utilize tumor-specific antigens to induce 
protective antitumor T cell immunity. Tumor antigens can be presented as free peptides or 
proteins, as whole cells or cell lysates, as DNA plasmid, or with antigen presenting cells pulsed 
with the antigen of interest [35-38].  
 Vaccines with free peptides or proteins alone have not been considerably successful or 
associated with a strong survival benefit in patients. This may be in part due to the rapid 
clearance of free peptides and lack of immune stimulation and presentation by antigen presenting 
cells, such as dendritic cells. Clinical studies with peptide vaccines are further limited by HLA-
restriction of patients to optimize peptide presentation. In 2011, the first phase III clinical study 
showing an effective clinical benefit with a peptide vaccine for advanced melanoma patients was 
published [39]. The clinical trial compared a gp100 peptide vaccine administered in incomplete 
Freund’s adjuvant followed by high dose interleukin-2 (IL-2) therapy to standard IL-2 therapy 
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alone. Significant improvement of progression-free survival (2.2 months vs. 1.7 months) and 
median overall survival (17.8 months vs. 11.1 months) resulted in the gp100 vaccine and IL-2 
group compared with IL-2 therapy alone. Similarly, promising results were observed in a phase 
II study with EGFRvIII peptide vaccination (CDX-110) of patients with newly diagnosed 
glioblastoma multiforme (GBM) following total tumor resection, radiation and temozolomide 
chemotherapy [40]. Median overall survival was extended to 26 months compared to 15 months 
for matched controls. Although improved time to progression was achieved (14.2 months vs. 6.3 
months), tumors recurred as antigen loss variants, EGFRvIII-negative tumors.  
 A different vaccine approach employs peptide-pulsed autologous dendritic cells alone or 
in combination with other agents such as stimulatory cytokines like granulocyte-macrophage 
colony-stimulating factor (GM-CSF). In summary, autologous dendritic cells loaded with tumor-
specific antigens are activated ex vivo and then re-infused into patients [41,42]. Recent FDA 
approval of sipuleucel-T (Provenge, Dendreon) has re-ignited interest in cell-based vaccines 
[43]. Sipuleucel-T is a cell-based product composed of peripheral blood mononuclear cells 
(PBMC) with a fusion protein of prostate acid phosphatase and GM-CSF. Although the phase III 
clinical trial yielded encouraging results, 4 months prolonged median survival, critical changes to 
cell-based vaccines must be implemented to improve therapeutic efficacy. Positive clinical 
outcome was demonstrated in a dendritic cell vaccine clinical study for metastatic melanoma 
[44]. In the clinical trial, melanoma patients received autologous dendritic cells incubated with 
irradiated autologous tumor cells and GM-CSF. Of 21 enrolled patients, 18 patients survived a 
median of 3 years and six patients experienced long-term survival with continued disease-free 
progression for up to 58 months following completion of the vaccine therapy. Dendritic cell 
vaccination strategies for glioma patients have not generated significant clinical responses and 
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had limited efficacy mostly associated with minor or partial responses [45-50]. While several of 
these vaccine trials have induced detectable immune responses of T cell proliferation, increased 
NK cells, and IFN-γ response, these have not correlated with improved clinical outcomes. 
 
1.3 Antibody-based immunotherapies 
 
 Antibody immunotherapy has emerged as a powerful and attractive modality by which to 
target melanoma, glioma, and other malignancies [51,52]. Therapeutic monoclonal antibodies 
(Ab) are available as unconjugated Abs or conjugated to cytotoxic agents like radioisotopes (e.g. 
125
I) and cellular toxins (e.g. Pseudomonas exotoxin), for targeted delivery of the toxic payload 
[30,53]. Several monoclonal Abs have gained regulatory approval as cancer therapy for B cell 
malignancies, breast cancer, metastatic colorectal cancer, refractory chronic lymphocytic 
leukemia, refractory acute myeloid leukemia, and metastatic melanoma to name a few [54-56]. 
Technological advances such as chimerization of murine Ab to express human Fc portions, 
humanization or expression of completely human monoclonal Abs have enhanced physiological 
Ab half-life, reduced induction of human anti-mouse antibodies (HAMA) and improved effector 
functions which mediate antibody-dependent cellular cytotoxicity (ADCC) [57].  
 Based on substantial clinical responses following depletion of malignant CD20
+
 B cells 
in patients with recurrent B-cell lymphoma, Rituximab (Biogen IDEC & Genentech), a chimeric 
Ab against the protein CD20, became the first FDA approved Ab for treatment of cancer 
malignancy [58-60]. Presently, it is utilized as the standard therapy for CD20-positive B-cell 
lymphoproliferative cancers with the exception of acute leukemia and myeloma. Although 
durable clinical responses resulted with Rituximab treatment as a monotherapy, the best clinical 
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outcomes were produced in combination with chemotherapy due to its effects on sensitizing cells 
to cytotoxic drugs [61-63]. Randomized trials of rituximab with chemotherapy have produced 
positive clinical responses in patients of numerous hematological malignancies including chronic 
lymphocytic leukemia, follicular lymphoma and diffuse large B-cell lymphoma [64-66]. In 1998, 
one year after FDA approval of Rituximab, a humanized Ab specific for human epidermal 
growth factor–2 (Her2), trastuzumab (Herceptin, Genentech) was the first monoclonal Ab to be 
approved clinically for the treatment of solid tumors (e.g. breast cancer) [67-69]. In patients 
whose tumors overexpress Her2 receptor, the monoclonal Ab prevents receptor dimerization thus 
blocking signal transduction and subsequent stimulation of cell proliferation [70]. No clinical 
study has been performed to investigate the clinical application of trastuzumab for glioblastoma 
but positive experimental results shows this strategy may be investigated for treatment of 
malignant glioma [71]. 
 Similar to trastuzumab, cetuximab (Erbitux, Bristol-Myers Squibb and Eli Lilly & 
Company) is a chimeric antibody which binds to epidermal growth factor receptors (EGFR) [72]. 
While cetuximab is clinically indicated for colorectal cancer and head & neck cancer, it was 
investigated in clinical trials with glioblastoma patients [73-75]. A clinical study in 2004 was 
unable to demonstrate significant correlation between cetuximab and survival for progressive 
high-grade glioma [76]. In contrast, in 2006 Belda-Iniesta and colleagues achieved long-term 
responses with cetuximab monotherapy in three patients with EGFR-positive glioma tumors 
[77]. Although EGFR is overexpressed in many glioma tumors, it is also expressed in normal 
tissue; a better target antigen would be expressed exclusively on neoplastic cells. An EGFR 
mutant, EGFRvIII, is absent in normal tissue yet expressed on 24-67% of glioblastomas and thus 
an attractive target [78,79]. This receptor variant can be recognized by cetuximab and showed 
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promising results in an experimental model [80]. Bevacizumab (Avastin, Genentech), originally 
indicated for colorectal cancer, has been approved for treatment of glioblastoma [81]. The 
humanized monoclonal Ab targets vascular endothelial growth factor (VEGF) to block 
angiogenesis and reduce the tumor’s vascular supply. The efficacy of this strategy has been 
demonstrated with improved progression free survival and effective clinical responses in patients 
with recurrent glioblastoma [82,83].  
 For advanced melanoma, a fully human monoclonal Ab that recognizes cytotoxic T 
lymphocyte antigen-4 (CTLA-4), ipilimumab (Yervoy, Bristol-Myers Squibb), was newly 
approved last year [84]. CTLA-4 expression is induced on T cells upon their activation to 
modulate T cell proliferation and regulate T cell responses. Blocking of CTLA-4 function 
thereby disinhibits T cell activation and allows the stimulation of tumor infiltrating lymphocytes 
(TIL). Non-specific lymphocytic activation mediated clinically significant benefits as reported in 
two clinical trials were improved survival and complete response was observed in some patients 
[85-87]. A disadvantage of uncontrolled T cell activation is off target toxicities due to T cell-
mediated autoimmune inflammation. Adverse events associated with ipilimumab include 
dermatitis, inflammatory bowel disease (e.g. colitis) and hypophysitis [88].  
 
1.4 Adoptive cell therapy 
 
 Tumor-specific immunity can be achieved through isolation and manipulation of immune 
cells which can then be re-infused into cancer patients. Following isolation, tumor-reactive 
autologous cells are expanded in vitro and introduced back into the patient directly into the 
tumor or systemically. Optimal results are attained in lymphodepleted patients pre-treated with a 
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chemotherapy and radiation regimen. Lymphodepletion eliminates regulatory T cells (Tregs), 
reduces competition for homeostatic cytokines, and improves persistence of transferred cells. 
Supporting evidence of a lymphodepleting regimen prior to adoptive cell therapy (ACT) has 
been clearly demonstrated with metastatic melanoma patients [89]. Different cell types have 
been investigated for adoptive cell therapy: lymphocyte-activated killer (LAK) cells, CTLs, or 
gene-modified T cells.  
 
1.5 Lymphocyte-activated killer cells 
 
 In the early 1980s, lymphocyte activated killer (LAK) cells were heavily examined as 
therapy for primary and metastatic cancers. Generally, peripheral blood lymphocytes were 
isolated and activated ex vivo in the presence of interleukin-2 (IL-2) and passively re-infused into 
patients. Phenotypic characterization of these activated cells revealed presence of stimulated T 
cells and natural killer (NK) cells. Immune responses with LAK effector cells were not 
completely tumor-specific as these cells exhibited cytolytic activity against a broad range of 
antigens. Encouraging results were observed in initial clinical studies with LAK in combination 
with IL-2 therapy but significant clinical benefits were limited. In a clinical study by Rosenberg 
and colleagues using LAK in conjunction with IL-2, a small survival improvement was observed 
in advanced melanoma patients while no survival benefit resulted for advanced renal cell cancer 
patients [90]. Furthermore, LAK and IL-2 therapy was associated with toxic adverse effects. For 
the treatment of glioma, significant clinical efficacy as determined by radiological responses did 
not correlate with clinical responses except in a few trials with intralesional delivery of LAK 
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cells [91,92]. Efforts to improve adoptive cell therapy and decrease its toxicity ongoing and may 
be achieved with antigen-specific TILs and genetically modified T cells. 
 
1.6 Cytotoxic T lymphocytes (CTLs) 
 
 CTLs can be obtained from stimulated peripheral blood mononuclear cells (PBMCs) or 
tumor infiltrating lymphocytes (TILs). For PBMCS, autologous tumor cells can be used as a 
source of antigen for ex vivo cell expansion and stimulation. TILs can be isolated from resected 
tumors, expanded and activated in vitro in the presence of IL-2, and re-infused into patients 
following a preparative lymphodepleting regimen (Fig. 1.1) [93]. In contrast to LAK cells, 
CTLs’ specificity for tumor-associated antigens results in potent immune responses with 
minimal adverse events. This therapeutic approach has been especially successful for the 
treatment of melanoma with patients demonstrating high response rates and durable, complete 
remissions. Harnessing the cytotoxic potential of T cells leads to powerful tumoricidal activity in 
an antigen-specific manner and thus reducing collateral damage to neighboring normal tissue. 
These exciting results make ACT with tumor-specific T cells an attractive strategy to mediate 
effective antitumor responses. A recent search of clinical trials in the NIH clinicaltrials.gov 
website indicated there are 69 studies with TILs that are currently ongoing or recently completed 
in the United States, Europe, and other countries around the world.  
 Transfer of TILs in combination with IL-2 produced remarkable results in 3 sequential 
trials with progressive metastatic melanoma. Of 93 patients, 52 experienced an objective 
response and 20 patients had complete tumor regressions, with 19 of those 20 having durable 
tumor eradication for a minimal of 3 years and up to 7 years [94]. These results highlight that 
ACT with TILs can achieve a high rate of complete tumor remissions and even possible cures for 
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patients with metastatic melanoma. CTL immunotherapy for glioma has been well tolerated and 
results from ten published trials achieved 28 partial responses and 3 complete responses from a 
total of 95 patients. Overall, administration of CTLs and TILs was superior to LAK cell infusion 
by targeting cytotoxicity directly to tumor cells and thus resulting in fewer adverse events. ACT 
with tumor-specific T cells is a potent strategy linked to effective therapeutic responses.  
  
1.7 Gene modified T cells 
 
A limitation of using TILs for adoptive cell immunotherapy is the difficulty in isolating T 
cells from tumors in certain patients. Melanoma tumors can efficiently induce tumor-reactive T 
cells throughout tumor progression and thus it is easier to harvest and expand tumor-specific T 
cells from melanoma patients. This is not the case for glioma patients whose tumors do not 
naturally stimulate significant numbers of antigen-specific T cells. To bypass this limitation, 
tumor-specific receptors can be introduced into T cells. Genetically engineered receptors can 
enhance T cell function and improve tumor targeting. Transfer of two types of gene modified 
receptors has been examined for their potential to re-direct T cells and enhance antitumor 
immunity: chimeric antigen receptors (CARs) and T cell receptors (TCRs) [95]. For this strategy, 
receptors against defined antigens are transduced into peripheral T cells, expanded ex vivo to 
therapeutic numbers and administered back into the patient.  
 
Chimeric antigen receptors (CARs) 
 CARs are composed of an extracellular, antigen-binding domain fused to an intracellular 
T cell signaling domain [96]. Similar to the binding portion of a monoclonal antibody, the 
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binding site of CARs recognize the targeted antigen with high affinity. The signaling domain 
usually consists of the zeta chain of the TCR/CD3 complex and its signal can be amplified by the 
addition of co-stimulatory molecules (e.g. CD28 and CD134). CAR-based T cell transfer 
strategies have the advantage of binding antigen in an MHC-unrestricted manner and thus are not 
restricted to targeting processed tumor antigens or limited by the tumor’s immune-evading 
mechanisms of downregulating MHC expression. Another benefit of CAR-engineered T cells is 
absence of mispairing of the introduced receptor chain with endogenous TCR chains, as can 
occur with full length heterodimer TCRs. CARs are single chain molecules and do not interact 
with endogenous TCRs expressed on modified T cells.  
CAR-engineered lymphocytes are presently being investigated for cancer 
immunotherapies [97-100]. There are 19 clinical trials currently recruiting patients, mostly for 
treatment of hematological malignancies but also for glioma, prostate cancer, and advanced lung 
cancer (August 2012 search, clinicaltrials.gov). Although a promising approach, there are 
potential drawbacks to utilizing CAR-based T cell therapies. CARs are limited to recognizing 
antigens restricted to the cell surface and cannot recognize processed antigens presented on 
MHC molecules. There is also the potential for immunogenicity as CARs are not fully human 
and immune responses can be elicited against the non-human sequences present in the chimeric 
receptors. Additionally, there is concern that off-target effects may result if targeted antigens are 
also expressed on normal tissue leading to immune responses against the host. A proposed 
measure to control this issue is to introduce safety mechanisms to specifically destroy CAR-
expressing cells in the event that off-target toxicities occur. 
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Genetically engineered TCRs 
 Positive clinical responses have also been obtained with genetically modified TCRs 
introduced into autologous or donor T cells [101-103]. Full length heterodimeric (α and β chains) 
TCRs can be introduced into polyclonal T cells or T cell subpopulations (CD8
+
 or CD4
+
 cells) 
through ex vivo transduction of the modified TCR genes in retroviral or lentiviral vectors [104-
107]. Transfer of antigen-specific TCRs fundamentally redirects the cells’ specificity to target 
the antigen of interest recognized by the introduced TCR. With TCR gene therapy, therapeutic 
quantities of tumor-specific T cells can be produced with great specificity for the target antigen. 
Genetic modifications of TCRs can generate TCRs of high affinities not present in the 
endogenous T cell repertoire. High affinity TCRs are deleted through a natural tolerogenic 
process to safeguard against auto-reactive T cells. Additionally, most tumor antigens are poorly 
immunogenic thus difficult to generate naturally arising T cells with high avidity TCRs. 
Genetically engineered high affinity TCRs can be transduced into peripheral cells ex vivo to 
ameliorate these issues. An additional advantage of TCRs, compared to CARs, is their antigen 
recognition in the context of MHC molecules. It allows TCR-transduced T cells to bind a wider 
repertoire of antigens, such as processed intracellular tumor peptides presented on MHC. 
 Concerns related with TCR gene therapy are based on off-target events observed in mice 
experimental studies. Unwanted graft-versus-host events may occur if alpha and beta chains 
from the introduced TCR pair with endogenous alpha and beta TCR chains. The pairing of mixed 
endogenous and introduced chains can generate TCRs with unknown specificities for host tissue 
and mediate undesirable immune responses [108]. Although, to date, similar complications have 
not been reported in human clinical studies, several strategies have been investigated to reduce 
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TCR chain mispairing [109-113]. As an alternative to the heterodimeric TCR gene transfer, 
Vα/Vβ single chain TCRs can be used to avoid mispairing [114,115]. The single chain TCRs 
express a stabilized variable TCR domain without TCR constant domains and thus eliminating 
binding of the transduced TCR with endogenous TCRs. Similar to CARs, the single chain TCR 
binding domain is linked to intracellular signaling domains which induce functional T cell 
activity. As a result, single chain TCRs are an attractive strategy for T cell immunotherapies.  
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CHAPTER TWO: 
 
DEVELOPMENT AND CHARACTERIZATION OF A NOVEL SIY-EXPRESSING 
MURINE GLIOMA TUMOR MODEL 
 
2.1 Introduction 
 
In 2012, 22,910 new cases of malignant brain and central nervous system (CNS) tumors 
are expected to be diagnosed in the United States [1]. Gliomas account for a majority of 
malignant primary CNS tumors and arise from glial cells. Glioblastoma multiforme (GBM) is the 
most aggressive form of malignant glioma; it is highly resistant to therapy and notorious for its 
capacity to invade normal brain structures. Its aggressive nature is associated with high mortality 
and very poor prognosis despite standard care consisting of surgery followed by radiation 
therapy and systemic chemotherapy with temozolomide [2]. Recurrence following treatment is 
common and may lead to tumor resistance to additional therapy. Currently, mean survival 
following diagnosis is 14.6 months while the overall 5-year survival rate following standard 
treatment is only 9.8% [3]. Therefore, development of new, effective therapies capable of 
targeting dispersed neoplastic cells throughout the brain while preserving normal brain 
parenchyma are necessary. 
 Alternative therapies that may be used in combination with standard treatment are 
currently being tested both experimentally and clinically. Our increasing knowledge of tumor 
immunology over the past few decades and our better understanding of the role the immune 
system plays in tumor recognition and eradication, has led to immunotherapies being 
investigated as a promising strategy for cancer treatment. With regards to glioma in particular, 
several scientific groups have explored various immunotherapies with promising results. Glioma 
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immunotherapies presently being investigated clinically include monoclonal antibodies, gene 
therapy, dendritic cell (DC) and peptide based vaccines, as well as adoptive T cell therapy. 
Adoptive transfer of T lymphocytes is highly attractive because T cells are able to penetrate the 
CNS and selectively recognize and destroy neoplastic cells. Although a promising approach, one 
of the limitations encountered clinically is the difficulty isolating and expanding tumor-specific 
T lymphocytes from patients. This limitation may be circumvented by genetically engineering T 
lymphocytes to express antigen-specific T cell receptors (TCR). Recent clinical trials with 
antigen-specific, gene modified T cells have already shown clinical benefit for treatment of 
cancers such as melanoma, synovial sarcoma and colorectal cancer [4-6]. Louis et al., recently 
reported complete remission in three of eleven patients treated with T cells expressing chimeric 
antigen receptors against a neuroblastoma associated peptide [7]. 
 Development of novel therapeutics for the treatment of glioma requires a reproducible 
murine experimental model to understand the mechanisms governing antitumor responses in 
glioma. A reliable tumor model that mimics human disease is essential for establishing effective 
cancer therapeutic modalities. For the past few decades, the GL261 glioma mouse model has 
been utilized for experimental research as an engrafted tumor model [8-12]. It resembles human 
glioma tumors in terms of neuropathology, invasive properties, angiogenesis, hypoxia, 
immunogenic antigens and other characteristics [13,14]. Unlike spontaneous tumor systems, the 
GL261 model is highly reproducible and mice consistently develop intra-cranial gliomas with a 
median survival of 27 days without treatment (unpublished data, Roy laboratory). 
In the present study, we modified the GL261 murine glioma cell line to express the SIY 
(SIYRYYGL) peptide, which is recognized by 2C T cells. 2C is a CD8
+
 T cell clone that 
recognizes and binds SIY peptide presented in the context of MHC I K
b
 (H2-K
b
) with an affinity 
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of 30 μM and it was originally isolated by Dr. David Kranz over 25 years ago [15,16]. This 
newly constructed glioma cell line, GL261-SIY, served as a model to investigate strategies to 
improve adoptive T cell therapy for brain tumors. We first characterized the GL261-SIY cell line 
both in vitro and in vivo and assessed T cell infiltration within subcutaneous (s.c.) and intra-
cranial (i.c.) GL261-SIY tumors. Our findings showed normal levels of H2-K
b
 compared to the 
parental GL261 cell line and elevated expression of SIY-K
b
 following interferon-gamma (IFN-γ) 
treatment. Co-incubation of GL261-SIY cells with SIY-specific T cells resulted in T cell 
activation as evidenced by interleukin-2 (IL-2) cytokine secretion. In addition to T cell 
activation, GL261-SIY cells were capable of inducing cytolytic T cell activity of activated 2C T 
cells in a cytotoxicity assay. In vivo characterization of GL261-SIY revealed extensive T cell 
infiltration of glioma tumors by both endogenous and adoptively transferred cells and 
preferential T cell homing to GL261-SIY tumor draining lymph nodes. Therapy with TCR gene 
modified T cells resulted in prolonged survival of tumor-bearing mice comparable to results 
observed with adoptive transfer of transgenic 2C T cells. Studies of adoptive T cell therapy with 
this new, SIY-expressing glioma model showed the potential of adoptive T cell immunotherapy 
as a selective treatment for targeting malignant glioma.  
 
2.2 Materials and Methods 
 
Mice 
C57BL/6 and C57BL/6 RAG1
-/-
 mice were originally purchased from The Jackson 
Laboratory (Bar Harbor, ME) and maintained as colonies in the animal facilities at the 
University of Illinois. We utilized immunodeficient RAG1
-/-
 mice (lacking B and T cells) as a 
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model representing a similar immunological state as that of patients in the clinical setting 
following radiation therapy prior to adoptive cell therapy (ACT). 2C T cell receptor (TCR) 
transgenic mice on the C57BL/6 background were maintained as a heterozygous colony and 
screened for expression of the 2C TCR on Thy1.2
+
 peripheral blood cells by flow cytometry 
analysis with 1B2 clonotypic antibody (Ab) [17,16]. Mice were 2-5 months of age at the time of 
experiments and all of the animal studies were approved by the Institutional Animal Care and 
Use Committee at the University of Illinois at Urbana-Champaign.  
 
Cell Lines 
The B16 F10 murine melanoma cell line was purchased from American Type Culture 
Collection (Manassas, VA) and B16-SIY murine melanoma cell line was a generous gift from 
Dr. Thomas Gajewski (University of Chicago, IL). B16-SIY cancer cells were derived by 
retroviral transduction of B16 F10 cells with a fusion protein of the K
b
-binding peptide SIY and 
enhanced green fluorescent protein (EGFP) [18]. The murine fibrosarcoma cell lines MC57 and 
MC57-SIY-Hi were also obtained from the University of Chicago. The murine glioma cell line 
GL261 was obtained from the National Cancer Institute-Frederick Cancer Research Tumor 
Repository (Frederick, MD). GL261-SIY cancer cells were derived by retroviral transduction of 
GL261 cells with a fusion protein of the K
b
-binding peptide SIY with EGFP in our lab 
(University of Illinois, Urbana-Champaign). m33 TCR-transduced 58
-/-
 T cell hybridomas were 
obtained from Dr. David Aggen in the Kranz laboratory [19]. All cancer cell lines are syngeneic 
to the C57BL/6 background and were grown in complete RPMI 1640 media (RPMI 1640 
supplemented with 5 mM HEPES, 10% Fetal Bovine Serum (FBS), 1.3 mM L-glutamine, 50 pM 
2-ME, penicillin, and streptomycin) at 37°C in 5% CO2 in a humidified incubator. 
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Transduction of GL261 cell line with SIYRYYGL gene 
Platinum-E (Plat-E) retroviral packaging cells were plated at 4 x 10
6
 cells per poly-L-
Lysine (Sigma) coated 10 cm petri dish and cultured for 24 h [20]. Plat-E cells were transfected 
with pMFG-EGFP-SIY vector, provided by Dr. Hans Schreiber (University of Chicago, IL), or 
with MLV-GFP-CD4 as a control vector provided by Dr. Paul Allen (Washington University, 
MO). pMFG-EGFP-SIY expresses SIY peptide fused to green fluorescent protein (EGFP) while 
MLV-GFP-CD4 expresses GFP-fused CD4. Plat-E cells were transfected with 40 μg vector 
DNA, transfection reagent Lipofectamine 2000 (Invitrogen) and complete RPMI 1640 media for 
4 h at 37°C. Following the transfection, the DNA-transfection mixture was aspirated and 6 ml of 
complete RPMI 1640 media were added to each plate. Viral supernatant was harvested 48 h after 
transfection, passed through a 0.45 μm syringe filter and 50 μl of Lipofectamine 2000 was added 
per 6 ml of viral supernatant. Filtered retroviral supernatant was added to plated GL261 glioma 
cells and centrifuged at 2,000 rpm at 30°C for 1 h. Following centrifugation, cells were incubated 
at 37°C in 5% CO2 in a humidified incubator and a second transduction was repeated 24 h later. 
Once transduced with SIY, GL261 cells were sorted (BD FACSAria) under sterile 
conditions. The first two sorts eliminated SIY negative cells by selecting GFP positive cells only. 
For the third and last sort, glioma cells were incubated with the SIY/K
b
 high-affinity binding 
single-chain TCR m67 (biotinylated) on ice for 1 h, washed and stained with streptavidin-
allophycocyanin (Invitrogen) for 30 min. The top 8% of m67 positive cells were isolated and 
expanded in culture.  
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Interferon gamma (IFN-γ) treatment and flow cytometry analysis of GL261-SIY cells 
Glioma cells were plated in a 6 well plate at a density of 7 x 10
5
 cells in 2 mL complete 
RPMI 1640 medium per well. Cancer cells were cultured with media only or with 10 ng/mL 
IFN-γ (eBioscience) for 24 h. Cells were stained with anti-K
b
 (B8.24.3 monoclonal antibody 
purified in the Kranz Laboratory) and soluble biotinylated single chain m67 to detect SIY 
peptide bound to H2-K
b
 at low concentrations on the surface of tumor cells. After 1 h incubation 
with anti-K
b
 or m67 at 4°C, cells were washed twice with 0.5% PBS/BSA and streptavidin-
allophycocyanin (Invitrogen) was added as secondary Ab for 30 min. Cells were washed twice 
with 0.5% PBS/BSA before analysis on Accuri C6 Flow Cytometer. 
 
T Cell Activation Assay (IL-2 release) 
96-well plates (Immulon 2HB) were coated with 2.5 μg/ml anti-murine IL-2 Ab (BD 
Pharmingen) in 0.1 M Na2HPO4 (pH 9) for 24 h at 4°C. Wells were washed three times with 
PBS containing 0.05% Tween 20 (PBST). After the washes, the plate was blocked with 1% BSA 
in PBS for 24 h at 4°C. Following the blocking incubation, wells were washed three times with 
PBST. On a separate plate, m33 TCR-transduced 58
−/−
 cells (5 x 10
4
) were incubated with one of 
several cell lines: GL261, GL261-SIY, B16 F10, B16-SIY, MC57, MC57-SIY-Hi, or 
immobilized anti-CD3 Ab (BD Pharmingen) at 5 μg/ml. Cancer cells were incubated with the 
m33 TCR-transduced 58
−/−
 cells at a ratio of 1:1 for 24 h at 37°C and 5% CO2 in triplicate wells. 
Supernatants were collected and 100 μl of cell supernatant were added to the IL-2 coated plate 
and incubated for 24 h at 4°C. Wells were washed three times with PBST and biotinylated anti-
murine IL-2 Ab (7 μg/ml, BD Pharmingen) in PBS was added and incubated for 1 h at room 
temperature. Wells were washed three times with PBST and incubated with a 1:10,000 dilution 
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of streptavidin-HRP (BD Pharmingen) in PBS for 30 min at room temperature. Finally, plates 
were washed three times with PBST and developed with 50 μl of tetramethylbenzidine substrate 
(Kirkegaard & Perry Laboratories) until a color change was seen in the control wells. The 
reaction was stopped with 50 μl of 1 N H2SO4 and absorbance at 450 nm was measured in each 
well using an ELx800 universal microplate reader (Bio-Tek Instruments). 
 
Cytotoxicity Assay 
2C T cells were obtained from spleens of 2C TCR transgenic mice and prepared into a 
single-cell suspension. Erythrocytes were lysed with ammonium chloride potassium buffer 
(ACK, lysing buffer) and splenocytes were incubated for 48 h with 1μM SIY peptide and 5% rat 
ConA supernatant (RCAS) to activate effector 2C T cells. Target murine glioma cells were 
incubated with 150 μl of 2 mCi/ml 51Cr for 2 h at 37°C in 5% CO2 in a humidified incubator and 
washed three times with complete RPMI 1640 media before incubating with 2C T cells at 10:1 
and 50:1 effector to target (E:T) ratios for 4 h. Chromium release was measured using a 
Beckman gamma counter and specific release was calculated using the formula: ((experimental 
release - spontaneous release)/(maximum release – spontaneous release)) x 100 
 
Subcutaneous (s.c.) glioma tumor cell implant and 2C T cell transfer 
Murine glioma cells were trypsinized, collected, and washed twice with sterile Hank’s 
Balanced Salt Solution (HBSS). A RAG1
-/-
 mouse was administered 4 x 10
6
 GL261 or GL261-
SIY cells/150 μl HBSS on the left and right flank under isoflurane (Baxter) inhalation anesthesia. 
Six days following tumor cell implant, 2C T cells were obtained from spleens of 2C TCR 
transgenic mice and prepared into a single-cell suspension. Erythrocytes were lysed with ACK 
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and T cells activated with anti-CD3 and anti-CD28 coated beads (Dynabeads, Invitrogen). After 
24 h, beads were magnetically removed, cells were washed twice with HBSS and 3.2 x 10
6
 T 
cells were administered intra-peritoneally 7 days post tumor cell implant. 
 
Immunohistology 
 Monoclonal antibody 1B2, specific for the 2C TCR, was purified from a hybridoma 
and biotinylated using a chemical biotinylation kit (Pierce Chemical Co) by the Kranz 
Laboratory. Rat anti-mouse CD8α (Ly-2) and rat anti-mouse CD4 antibodies were purchased 
from eBioscience. DyLight 488-conjugated AffiniPure F(ab')2 Fragment donkey anti-rat IgG (H 
+ L) and Strepavidin-HRP (SA-HRP) were purchased from Jackson ImmunoResearch 
Laboratories. Streptavidin-Alexa 594 and 4,6-diamidino-2-phenylindole (DAPI) were obtained 
from Invitrogen. 
 Mice were sacrificed 4 days (s.c. tumor) or 3 days (i.c. tumor) following transfer of 
transgenic 2C T cells.  The tumors and lymph nodes were embedded in OCT medium and 
frozen. Staining was performed on 8-micron cryostat sections, mildly fixed by incubation in 95% 
ethanol at -20°C for 20 min and endogenous peroxide quenched by incubation in 0.3% H2O2 in 
methanol for 5 min.  Blocking was done with SuperBlock (ThermoScientific) and 5% normal 
serum of the species of the secondary antibody.  Anti-CD8, anti-CD4 and 1B2 primary 
antibodies were applied at 5–10 μg/ml for 24 h in blocking solution overnight.  Tissue sections 
were incubated with secondary antibodies for 45 min and counterstained with 4,6-diamidino-2-
phenylindole (DAPI, Invitrogen).  Tissue stained with 1B2 mAb were amplified with SA-HRP, 
tyramide-biotin and streptavidin-Alexa 594 and counterstained with DAPI. 
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Isolation and Activation of Primary Murine CD8
+
 T Cells 
Spleens from C57BL/6 mice were harvested, homogenized, and passed through a 100 μm 
mesh filter to obtain a single-cell suspension. Cells were washed once with complete RPMI 1640 
media and erythrocytes lysed by the addition of ACK. CD8
+
 T lymphocytes were negatively 
selected by magnetic sorting using the Mouse CD8α+ T Cell Isolation Kit II (MACS, Miltenyi 
Biotec). For activation, CD8
+
 T cells were plated in a 24-well dish at a concentration of 1 x 10
6
 
cells per well in 1 ml of T cell media. Each well with 1 x 10
6
 CD8
+
 T cells was incubated with 
25 µl of anti-CD3/anti-CD28 mouse T-activator Dynabeads (Invitrogen), in addition to 30 U of 
recombinant mouse IL-2 (Roche) for 24 h at 37°C and 5% CO2. 
 
Transduction of primary murine CD8
+
 T cells with 2C TCR gene 
Plat-E retroviral packaging cells were plated at 4 x 10
6
 cells/dish on a poly-L-Lysine 
(Sigma) coated 10 cm petri dish and cultured for 24 h. Plat-E cells were transfected with 2C TCR 
gene, cloned into the pMP71 vector (from myeloproliferative sarcoma virus, MPSV) as 2C beta 
chain-P2A-2C alpha chain using NotI at the 5'-end and EcoRI at the 3'-end [21]. The 2C TCR 
gene was codon optimized for expression in murine cells. Plat-E cells were transfected with 40 
μg vector DNA, Lipofectamine 2000 (Invitrogen) and Opti-MEM (Invitrogen) for 4 h, after 
which the DNA-transfection mixture was aspirated and 6 ml of cell culture media added to each 
plate. Viral supernatant was harvested 48 h after transfection, passed through a 0.45 μm syringe 
filter and 50 μl of Lipofectamine 2000 added per 6 ml of viral supernatant. Dynabeads were 
magnetically removed from activated CD8
+
 T cells and a 24-well plate was coated with 
Retronectin at 15 µg/ml (Takara, Japan). To each retronectin-coated well, 1 x 10
6
 CD8
+
 T 
cells/1ml T cell media was added with 1 ml sterile viral supernatant and 60 U of recombinant 
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murine IL-2. The plate was centrifuged at 2,000 rpm at 30°C for 1 h. Following centrifugation, 
cells were incubated at 37°C in 5% CO2 in a humidified incubator and a second transduction was 
repeated 24 h later. 
 
Flow Cytometry Analysis of Transduced CD8
+
 T Cells 
Seventy two hours after the first transduction, CD8
+
 T cells were analyzed by flow 
cytometry for expression of the 2C TCR and CD8 co-receptor. T cells were collected from the 
24-well dish and washed once with 0.5% PBS/BSA. Mock transduced and 2C TCR transduced T 
cells were incubated with biotinylated 1B2 Ab, Phycoerythrin (PE) labeled anti mouse CD8α 
(BD Pharmingen), or dual stained with 1B2 and anti-CD8α antibodies at a concentration of 10 
μg/ml for 1 hr at 4°C. After washing the cells twice with 0.5% PBS/BSA, Strepavidin-647 
(Invitrogen) was added at 10 μg/ml to1B2 stained T cells and incubated for 45 minutes at 4°C. T 
cells were washed twice with 0.5% PBS/BSA and analyzed on Accuri C6 Flow Cytometer. 
 
Intracranial Cancer Cell Infusion and 2C T cell transfer 
Murine glioma cells were trypsinized and collected, washed twice with sterile HBSS, and 
stereotaxically infused into the brain. RAG1
-/-
 received an infusion of 5 x 10
4
 cells in 300 nl (T 
cell infiltration experiment) and 8 x 10
4
 cells in 500 nl (Survival experiment) into the right 
ventral striatum (from bregma: 0.5 mm rostral; 2.5 mm lateral; 4 mm ventral). Transgenic 2C T 
cells were obtained from spleens of 2C TCR transgenic mice and prepared into a single-cell 
suspension. Erythrocytes were lysed with ACK and T cells activated with RCAS and 1 μM SIY. 
After 24 h, cells were washed twice with HBSS and 1 x 10
7
 2C T cells were administered 
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intravenously (i.v.) 11 days post-tumor cell implant (T cell infiltration experiment) or 8.1 x 10
6
 
2C T cells i.v. 10 days post-tumor cell implant (Survival experiment). 
 
Statistical analyses 
GraphPad Prism software was used to analyze survival curves by log-rank (Mantel-Cox) 
test. Significance was considered p < 0.05.  
 
2.3 Results 
 
Retroviral transduction of murine glioma cell line with SIYRYYGL peptide 
To utilize the GL261 murine glioma cell line as a brain tumor model for adoptive cell 
therapy with 2C T cells, GL261 cells were retrovirally transduced to express the SIYRYYGL 
(SIY) peptide. Presentation of SIY in the context of MHC I H2-K
b
 is recognizable by T cells 
expressing the 2C TCR [22]. The murine glioma cell line was retrovirally transduced using 
supernatant from transfected Plat-E retroviral packaging cells. Plat-E cells were transfected with 
either pMFG-EGFP-SIY vector or with MLV-GFP-CD4 as a control vector. pMFG-EGFP-SIY 
expresses SIY peptide fused to green fluorescent protein (GFP) while MLV-GFP-CD4 expresses 
GFP-fused CD4. Effective Plat-E transfection with both vectors was verified with fluorescent 
microscopy (Fig. 2.1). Positive GFP fluorescence of Plat-E cells confirmed the successful 
transfection with both vectors.  
Viral supernatant was harvested from the transfected Plat-E cells and GL261 cells were 
transduced with SIY. Following the first transduction, additional viral supernatant was collected 
from Plat-E cells and a second transduction was performed. Effectiveness of transducing GL261 
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cells to express SIY as a GFP-fusion protein was assessed by GFP fluorescence (Fig. 2.2). Few 
green fluorescent cells were present one day post-transduction but the number of GFP-positive 
cells greatly increased with time in culture. GL261-SIY cells were isolated from SIY negative 
cells by fluorescence-activated cell sorter (FACS) selection of GFP positive cells. Following two 
sorting cycles on positive GFP fluorescence, glioma cells were stained with the SIY/K
b
 high-
affinity single-chain TCR m67 and the top 8% of m67 positive cells were selected (data not 
shown). Overall, cells were sorted three times to eliminate GFP negative cells and enhance the 
cells expressing SIY-K
b
. The end result yielded GFP
+
 SIY/K
b+
 GL261 cells: a murine brain 
tumor model for adoptive T cell therapy with the 2C-SIY/K
b
 model system. 
 
Characterization of SIY expression by GL261-SIY cell line 
 We proceeded to characterize GL261-SIY in vitro and measure the levels of H2-K
b
 and 
SIY peptide/H2-K
b
 on the surface of GL261-SIY cells, as well as of the parental cell line GL261 
for comparison. Cells were evaluated for H2-K
b
 expression with anti-K
b
 antibody (B8.24.3) and 
for SIY peptide/H2-K
b
 expression with biotinylated m67 TCR monomer staining. Flow 
cytometric analysis revealed slightly higher basal H2-K
b
 levels on GL261-SIY cells compared to 
GL261 but similar upregulation of H2-K
b
 on both cell lines following IFN-γ treatment (Fig. 
2.3a). Although GL261-SIY cells displayed high H2-K
b 
expression, they expressed low levels (~ 
23%) of SIY peptide/H2-K
b
 on the surface. As expected, SIY peptide/H2-K
b
 expression was 
absent on untransduced parental GL261 cells. However, IFN-γ treatment resulted in SIY 
peptide/H2-K
b
 upregulation on GL261-SIY cells by 2.3 fold and had no effect on untransduced 
parental glioma cells (Fig. 2.3a). Assessment of GFP expression clearly shows high GFP 
fluorescence by GL261-SIY cells while parental GL261 does not express GFP (Fig. 2.3b). These 
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results demonstrate the successful transduction of the GL261 murine glioma cell line to express 
SIY peptide. From these results, we can also conclude that IFN-γ is important for high 
expression of SIY peptide/H2-K
b 
on the surface of GL261-SIY. In terms of in vivo studies, this 
suggests that IFN-γ cytokine release by tumor associated cells may be necessary for optimal SIY 
peptide presentation and subsequent T cell recognition.  
 
GL261-SIY efficiently expresses SIY peptide resulting in activation and cytolytic activity of T 
cells in vitro 
 Green fluorescence expression as evidenced in microscopy images and flow cytometry 
analysis of SIY peptide/H2-K
b 
corroborate the successful retroviral transduction of parental 
GL261 glioma cells into a SIY-expressing cell line. However, it is important to determine 
whether the interaction of the 2C TCR with SIY peptide presented in the context of the class I 
MHC K
b
 is functional. To examine the interaction of T cells with SIY-expressing glioma cells, 
we measured cytokine secretion by 58
-/-
 T cells expressing the SIY/K
b
 high affinity TCR m33 in 
response to co-incubation with GL261-SIY cells. Recognition of SIY peptide/H2-K
b
on the 
surface of glioma cells should result in activation of the T cells and subsequent secretion of 
cytokines. For comparison of cytokine expression levels, we also tested murine melanoma and 
fibrosarcoma (parental and SIY-expressing) tumor cells. Following a 24 h co-incubation of m33 
58
-/-
 T cells with cancer cells, Interleukin-2 (IL-2) cytokine levels were quantified from cell 
culture supernatants (Fig. 2.4a). None of the parental tumor cell lines (GL261, B16 F10, and 
MC57) stimulated IL-2 secretion by high affinity m33 58
-/-
 T cells. The cell lines which 
produced the greatest activation were the three SIY-expressing tumor cell lines: GL261-SIY, 
B16-SIY, and MC57-SIY Hi. Cytokine expression by T cells was similar in response to GL261-
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SIY, B16-SIY, and MC57-SIY Hi cell lines. This data validates that the interaction of m33 TCR 
with the tumor peptide/MHC is functional, as evidenced by IL-2 expression of T cells in 
response to co-incubation with GL261-SIY but not with the parental GL261 glioma cell line. 
 In addition to assessing T cell activation, we evaluated the cytotoxic effector function of 
transgenic 2C T cells against parental GL261 and GL261-SIY in vitro. Chromium release was 
measured from supernatant of 
51
Cr-labeled glioma cancer cells incubated for 4 hours with 
activated 2C T cells at two different effector to target cell (E:T) ratios (Fig. 2.4b). SIY peptide on 
GL261-SIY was specifically recognized and the cells killed by 2C T cells but not the parental 
cell line GL261. Lysis of GL261-SIY cells was similar at both an E:T ratio of 10:1 and 50:1 
(17% and 19%, respectively). Overall, the reported responses of 2C T cell cytolytic activity 
against GL261-SIY demonstrate efficient presentation of SIY peptide by GL261-SIY cells. Most 
importantly, activation of T cells by GL261-SIY cells resulting in cytokine secretion, as well as 
antigen-specific cytotoxic T cell activity against SIY-expressing glioma cells, establish a 
functional interaction of T cells and SIY peptide/H2-K
b 
on GL621-SIY cells in vitro.  
 
Transgenic 2C T cells preferentially infiltrate subcutaneous GL261-SIY tumors 
 Cytokine secretion and activation of cytolytic activity of T cells are important 
components in inducing effective antitumor immunity but in vitro T cell function does not 
always correlate with in vivo antitumor immune response. For this reason, we investigated 
whether established subcutaneous (s.c.) GL261-SIY tumors were targeted and infiltrated by 2C T 
cells in vivo. We implanted parental GL261 on one flank and GL261-SIY on the contralateral 
flank of a RAG1
-/-
 mouse and allowed the tumors to become established for 7 days. Once tumors 
were established, 2C T cells labeled with the near infrared membrane permeable dye NIR-815 
43 
 
were administered intravenously. Four days after adoptive transfer of T cells, the tumors were 
harvested and scanned with an infrared imager to detect NIR-labeled 2C T cells’ infrared 
fluorescence. The GL261-SIY tumor’s diameter had decreased and dye-labeled T cells were 
present throughout the tumor tissue (Fig. 2.5a). Although 2C T cells were also present in the 
GL261 tumor, there were fewer T cells and only localized in the peripheral region of the tumor. 
Compared to GL261, 2C T cells more efficiently controlled GL261-SIY tumor growth and 
generated a more robust tumor infiltration. 
To confirm that infrared fluorescence detected as T cells in the infrared scanned tissue 
were in fact 2C T cells, the same tissue was processed for immunohistology. The tumors were 
labeled with 1B2 clonotypic antibody, which recognizes 2C TCR, and with an antibody against 
murine CD8
+
 (Fig. 2.5b-g). 2C T cells were indeed present in the glioma tumors and matched the 
NIR fluorescence in the infrared scanned image. Examination of the parental GL261 tumor tissue 
showed few 2C CD8
+
 T cells and these localized mainly around the rim of the tumor. In contrast, 
GL261-SIY tumor tissue had massive 2C CD8
+
 T cell infiltration throughout the tumor. These 
findings indicate that 2C T cells recognize and preferentially infiltrate GL261-SIY glioma cells 
subcutaneously and that greater T cell infiltration of GL261-SIY tumor contributes to the anti-
tumor effect of 2C T cells in controlling GL261-SIY tumor growth compared to GL261 tumor. 
 
Transgenic 2C T cells preferentially home to GL261-SIY tumor draining lymph node 
 Lymph nodes play a pivotal role in triggering cellular immune responses. Lymphoid 
compartments provide a site for antigen presenting cells to interact with T lymphocytes. Antigen 
presentation to T cells leads to their activation and propagation, generating an effective adaptive 
immune response. Tumor draining lymph nodes in particular are a rich source of immune T cells. 
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For this reason, we analyzed the persistence of T cells in the tumor draining lymph nodes of both 
parental GL261 and GL261-SIY tumors.  We implanted bilateral subcutaneous tumors: parental 
GL261 and GL261-SIY, and allowed the tumors to become established. One week after tumor 
implant, 2C T cells were adoptively transferred and the draining inguinal lymph nodes for each 
respective tumor were harvested four days later. Tumor draining lymph nodes were labeled with 
1B2 clonotypic antibody and DAPI as counterstain (Fig. 2.6). Upon examination of the lymphoid 
tissue, it was clear that 2C T cells were abundantly present in the GL261-SIY tumor draining 
lymph node (Fig. 2.6a-c), consistent with lymphocytic proliferation. In contrast, the GL261 
tumor draining lymph node showed minimal infiltration of 2C T cells (Fig. 2.6d-e), suggesting 
that these T cells preferentially traffic to the GL261-SIY tumor draining lymph node. 
Furthermore, comparison of microscopy images of both tumor draining lymph nodes at the same 
magnification clearly showed a larger GL261-SIY tumor draining lymph node compared to the 
lymph node associated with the GL261 parental tumor. Together, this data indicates there is a 
preferential homing of peptide-specific T cells towards the SIY tumor draining lymph node as 
well as proliferation of these cells within the lymph nodes.  
 
Intracranial GL261 tumors expressing SIY peptide are infiltrated by CD4
+
, CD8
+
 and 2C T cells 
 Subcutaneous studies of the SIY-expressing glioma model allowed us to further 
investigate the in vivo interactions of 2C T cells with GL261-SIY tumor cells. However, to 
utilize GL261-SIY as a brain tumor model for studying adoptive T cell therapy, it was essential 
that we evaluated this cell line intra-cranially. An immunocompetent C57BL/6 mouse was 
implanted with GL261-SIY cells into the right striatum and a tumor was allowed to become 
established for 11 days. Activated, transgenic 2C T cells were administered intravenously and 
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brains and lymph nodes were harvested 3 days following adoptive cell transfer. Histology of 
both brain and lymphoid tissue entailed dual stain with clonotypic 1B2 antibody and anti-murine 
CD8 antibody to detect both 2C TCR as well as CD8
+
 T cells, respectively. 
Immunohistochemistry showed GL261-SIY brain tumors greatly infiltrated by 1B2 positive 2C 
T cells (Fig. 2.7a and c). CD8 staining revealed extensive infiltration of CD8
+
 T cells throughout 
the tumor (Fig. 2.7b and c), some of which were endogenous C57BL/6 cells (2C negative) while 
others were adoptively transferred 2C CD8
+
 cells seen as yellow in merged microscopy images 
(Fig. 2.7c). 1B2 and CD8 positive cells were not only present within the brain tumor but in the 
lymph nodes as well (Fig. 2.7d-f).  
Brain tumor and lymphoid tissue were also analyzed for infiltration by 2C and CD4
+
 T 
cells. Both lymph nodes and GL261-SIY tumors were labeled with 1B2 and anti-murine CD4 
antibody for the detection of CD4
+
 T cells. Similar results were observed with 2C T cells, which 
were found abundantly in GL261-SIY brain tumors (Fig. 2.8a and c). Extensive CD4
+
 T cell 
infiltration was also observed, mostly in close association with 2C T cells (Fig. 2.8b and c). 
Whether these CD4
+
 T cells were helper T cells or regulatory T cells it is still unclear and needs 
to be further investigated. It is likely these cells may be of a regulatory phenotype as glioma cells 
can induce an immunosuppressive environment through the secretion of inhibitory cytokines (i.e. 
TGF-β) [23]. In the lymphoid tissue, 2C T cells (Fig 2.8d and f) were also present while 1B2 
negative CD4
+
 T cells (Fig. 2.8e and f) were plentiful, as expected in an immune competent 
C57BL/6 mouse. Together, these findings confirm that GL261-SIY cells can develop into a brain 
tumor in an immunocompetent mouse, that adoptive therapy with 2C T cells results in successful 
infiltration of GL261-SIY brain tumors as well as lymph nodes, and that endogenous CD4
+
 and 
CD8
+
 T cells in an immunocompetent mouse are recruited to GL261-SIY brain tumors.  
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Anti-tumor immune effects of transduced primary murine T cells in the GL261-SIY tumor model 
 Based on the in vivo findings with GL261-SIY, we sought to determine whether 2C T cell 
infiltration, as observed subcutaneously and intra-cranially, would translate into significant long-
term anti-tumor immune effects. The SIY peptide/2C TCR system, although an excellent system 
for the study of adoptive T cell therapy of various SIY expressing tumor models, is not directly 
clinically applicable. Consequently, we investigated the therapeutic efficacy of primary T cells 
with genetically engineered TCRs; a method currently being tested for cancer treatment in 
clinical trials. As a comparison to transgenic 2C T cell therapy, primary polyclonal murine CD8
+
 
T cells were retrovirally transduced with the 2C TCR. Briefly, CD8
+
 T cells were isolated from 
C57BL/6 mice splenocytes and activated with anti-CD3/anti-CD28 coated beads. Next, T cells 
were transduced with retroviral supernatant containing the wild-type 2C TCR. Flow cytometry 
analysis of CD8
+
 T cells 3 days post-transduction was utilized to assess the expression of 2C 
TCR, verify successful isolation of CD8
+
 T cells, and determine the transduction efficiency of 
the CD8
+
 T cells (Fig. 2.9). Transduced T cells were single and dual labeled with 1B2 and anti-
murine CD8
+
 antibodies. Isolation of CD8
+
 T cells was successful as evidenced by a > 90% 
CD8
+
 population (Fig. 2.9a). T cell transduction was verified with 2C expression, about 37% 
positive (Fig 2.9b), and confirmed dual expression of CD8 and 2C TCR (Fig. 2.9c). 
In order to compare transduced primary T cells with transgenic T cells, we utilized first 
transgenic 2C T cells to assess the effect of these cells on survival of tumor bearing mice.  
RAG1
-/-
 mice were inoculated with GL261-SIY brain tumors and treated with either saline (n = 
3), as control, or pre-activated transgenic 2C T cells (n = 4) 10 days post-tumor cell implant (Fig. 
2.10a).  In comparison to saline control (mean 28 days), survival time was significantly extended 
with transgenic 2C CD8
+
 T cell treatment (mean 72 days). For comparison, 2C TCR-transduced 
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CD8
+
 T cells were adoptively transferred into RAG1
-/-
 mice bearing glioma brain tumors for 10 
days, as was performed with transgenic 2C T cells. Mice were saline (n = 3) or activated 
transduced 2C CD8
+
 T cell (n = 4) treated (Fig. 2.10b). We found a significant survival 
prolongation with transduced 2C CD8
+
 T cells compared to saline treatment (mean survival 49 
days versus 27 days). Overall, we discovered that both treating with transgenic 2C CD8
+
 or 
transduced 2C CD8
+
 T cells provide a significant survival advantage for mice with established 
brain tumors. Transgenic T cells in this model had a more robust prolongation of survival than 
transduced 2C CD8
+
 cells and this could be in part to a greater percentage of adoptively 
transferred transgenic cells expressing 2C TCR compared to 35% transduction efficiency with 
transduced 2C CD8
+
 primary T cells. Regardless of the cell therapy, transgenic vs. genetically 
engineered T cells, all mice ultimately succumbed to glioma tumors. It is important that in the 
future, we further investigate whether antigen loss variants are responsible for tumor relapse in 
this model. In summary, these experiments clearly show that transduced T cells can be applied as 
an effective adoptive cell therapy of brain tumors. More specifically, transduced 2C CD8
+
 T cells 
can generate a substantial anti-tumor immune response against this brain tumor model. 
 
2.4 Discussion 
 
 The SIY-expressing glioma cell line, GL261-SIY, served as an important murine research 
model to study experimental glioma immunotherapies. Through retroviral transduction, we 
successfully modified the parental GL261 cell line to functionally express the SIY peptide. 
Following glioma cell transduction, enrichment of SIY
+
 cells was performed with cell sorting for 
GFP and SIY-K
b
 expression. Characterization of SIY-K
b
 complexes on GL261-SIY revealed a 
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key role of IFN-γ in up-regulation of SIY peptide presentation and subsequent T cell recognition. 
IFN-γ has been demonstrated to have an essential part in immunomodulation and in the 
generation of effective antitumor activities. Indeed, this cytokine plays a key role in activating 
antigen presenting cells, stimulating immune cells’ cytotoxic activity, and enhancing peptide-
MHC surface expression. Consequently, IFN-γ has been used alone and in combination with 
other immune-stimulating cytokines, such as IL-2 and GM-CSF, as a therapeutic approach 
against gliomas [24-27]. This highlights the possibility of using IFN-γ in combination with other 
immune-based therapies such as adoptive T cell therapy. T cells themselves secrete IFN-γ and a 
positive correlation has been demonstrated between T cell-mediated immunological responses 
and clinical outcome of cancer patients [28]. 
 The functional expression of SIY peptide on glioma cells was evaluated using an IL-2 
cytokine release assay and a standard 
51
Cr-release cytotoxicity assay. Results from these two 
tests confirmed effective T cell activation by GL261-SIY cells and peptide-specific killing of 
these SIY-expressing cells. Furthermore, we demonstrated that SIY-specific T cells can 
effectively recognize GL261-SIY cells in vivo and thus preferentially infiltrate SIY-expressing 
tumors and not parental GL261 tumors lacking this peptide. Tumor infiltration by effector T cells 
is crucial for the initiation and maintenance of antitumor immunity. As reported by Lohr et al., 
improved survival of glioblastoma patients is directly correlated with tumor infiltration by 
elevated numbers of cytotoxic and helper T cells [29]. Elevated numbers of T lymphocytes can 
be achieved through T cell stimulation at tumor draining lymph nodes, as we observed with 2C T 
cells preferentially homing to GL261-SIY-associated lymph nodes. 2C T cells proliferated and 
resulted in enlarged SIY-draining lymph nodes compared to GL261 parental draining lymph 
nodes.  
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 In an immunocompetent model, endogenous CD4
+
 T cells were present in an intracranial 
GL261-SIY tumor and associated with adoptively transferred 2C CD8
+
 T cells. Intratumoral 
infiltration by CD4
+
 T cells is very significant as these cells have a critical role in survival, 
infiltration and proliferation of tumor-associated CD8
+
 cytotoxic T lymphocytes (CTLs). Thus 
recruitment of CD4
+
 helper T cells to the tumor site is crucial for generating an effective 
antitumor immune response [30-35]. To further examine CD4
+
 T cells for adoptive therapy, in 
future experiments we will investigate whether ACT with CD4
+
 helper T cells has a direct effect 
on gliomas in addition to enhancing antitumor effector functions of CD8
+
 CTLs for cancer 
therapy. High affinity class I-restricted TCRs (activity independent of CD8 co-receptor) 
engineered in the Kranz laboratory can be introduced into CD4
+
 helper T cells to redirect them to 
recognize MHC class I restricted antigens. The high affinity m33 TCR, like 2C TCR, recognizes 
SIY-K
b
 expressed on the surface of B16-SIY murine melanoma cells and GL261-SIY murine 
glioma cells. These SIY-expressing cell lines can serve as metastatic and primary brain tumor 
models and can be employed to evaluate whether CD4
+
 helper cells transduced to express a class 
I-restricted TCR engineered for high affinity will synergize with CTLs to eliminate malignant 
brain tumors and enhance T cell immunotherapy. 
 Although ACT treatments with CD4
+
 cells were not performed in this study, we did 
investigate ACT with CD8
+
 T cells. Anti-tumor effects of both transgenic and transduced 2C 
CD8
+
 T cells were demonstrated with glioma tumor-bearing mice. We showed that systemic 
delivery of transgenic or transduced primary murine CD8
+
 T cells expressing the 2C TCR were 
able to infiltrate brain tumors and significantly delay tumor growth; providing supporting 
evidence that transduced 2C T cells can specifically recognize glioma cells in an in vivo brain 
tumor model expressing SIY. These results were especially exciting since little research has been 
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published on the use of transduced primary T cells for the treatment of gliomas. Currently, 
reports on utilizing redirected cytotoxic T cells to target gliomas primarily focus on T cell 
transduced with chimeric receptors (antibody variable fragment coupled to T cell signaling 
domain) against tumor-associated peptides such as EGFRvIII and HER2 [36-39].  
Cancer therapy with transduced T cells provides an advantage over other T cell therapies. 
In the literature, two types of T cells have been reported as being administered into patients as 
treatment for brain tumors: CTLs (tumor-infiltrating lymphocytes (TIL) or isolated from PBMC) 
and lymphocyte-activated killer (LAK) cells. LAK were the first type of immunological cells 
adoptively transferred into glioma patients [40]. To obtain LAK cells, patients’ peripheral 
lymphocytes are isolated and stimulated with IL-2 to enrich a population of both natural killer 
(NK) cells and T cells capable of lysing tumor cells in a non-antigen specific manner. Because of 
the LAK cells’ non-specific cytolytic activity, it may result in lysis of non-malignant cells. For 
this reason, it is advantageous to target T cells’ cytotoxic activity against malignant cells and 
spare normal brain parenchyma by transducing T cells with a tumor peptide-specific TCR. As 
with LAK cells, there are limitations to using CTLs isolated from resected tumors (e.g. TILs). 
This procedure is efficient only when the tumor induces significant numbers of TILs during 
tumor progression, as is the case with melanoma but less likely with glioma tumors.  
 Overall, this chapter discussed the characterization and validation of a new glioma tumor 
model. This murine glioma cell line provided a peptide-specific and unique tumor model, as well 
as contributed significantly to our understanding of adoptive T cell therapies for intracranial 
tumors. Good experimental cancer models are indispensable for translational research as they 
help expand our knowledge of the mechanisms that govern antitumor immunity. Combining 
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immune-based therapies with standard multimodal treatment will hopefully achieve cures or 
improved clinical results for patients with gliomas.  
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CHAPTER THREE: 
 
MHC-CLASS I-RESTRICTED CD4 T CELLS: A NANOMOLAR AFFINITY TCR HAS 
IMPROVED ANTI-TUMOR EFFICACY IN VIVO COMPARED TO THE 
MICROMOLAR WILD TYPE TCR 
 
3.1 Introduction 
 
It has been suggested that combined recruitment of CD8
+
 and CD4
+
 T cells to tumors can 
improve responses and generate long-term memory [1-3]. Infiltration of CD4
+
 T cells can 
provide a cytokine milieu favorable to inducing proliferation, survival and effector function of 
CD8
+
 T cells within tumors as well as induce the activation of the innate immune system [4-8]. 
Additionally, CD4
+
 cells are capable of mediating cytotoxic activity, directly eradicating 
melanoma tumors, and can indirectly elicit tumor inhibition through IFN-γ-dependent effects on 
host cells [9-12]. CD4
+
 T cell activities at the site of a tumor could also provide an inflammatory 
environment that is favorable to the induction of human T cell responses [13,14].  
A major problem with the recruitment of CD4
+
 T cells is that most tumors do not express 
class II MHC, thereby preventing direct recognition and activities associated with CD4
+
 T cells. 
To overcome this challenge, TCRs have been engineered with higher affinity for a class I tumor 
antigen, avoiding the requirement for CD8 co-receptors, and thereby mediating CD4
+
 T cell 
activities [15-20].  
Efforts to introduce αβ TCR genes into T cells activated ex vivo for cancer therapy have 
generated considerable excitement [21-26]. In the well-studied system that targets melanoma 
antigen MART-1/HLA-A2, two different TCRs have been used clinically, DMF4 and second-
generation DMF5 [21,27,22]. Despite promising results with these TCRs, it is not yet clear 
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whether even DMF5 represents an optimal TCR. For example, both DMF4 and DMF5 have 
relatively low affinities, with Kd values of 170 µM and 40 µM, respectively [28], and while 
DMF5 promotes activity of CD4
+
 T cells it is not clear if the magnitude of this activity is 
optimal. In addition, it is not known if TCRs with different affinities against class I MHC will 
mediate lineage commitment of different CD4
+
 subsets. 
Experiments in vitro suggest that optimal co-receptor independent activation, for 
directing CD4
+
 T cell activity by a class I pepMHC-specific TCR, occurs at higher affinities, in 
the range of 0.5-3 µM [18,20]. However, affinities of most anti-tumor TCRs have not been 
measured, largely due to problems with expression of soluble TCRs and the normally very low 
affinity of TCRs for their cognate pepMHC antigens. In addition, recent evidence suggests that 
the behavior of T cells in vivo may not be completely predictable by activities in vitro [29,30]. 
The activity of TCR-transduced CD4
+
 T cells in vivo, with well-characterized TCRs requires 
study. 
To examine the role of TCR affinity in adoptive T cell therapies, we took advantage of 
the well-studied 2C TCR, specific for class I MHC K
b
 bound to foreign peptide SIYRYYGL 
(SIY, Kd = 30 µM), and its high-affinity TCR variant called m33 (Kd = 30 nM) [31]. Our recent 
results showed that CD8
+
 T cells with the m33 TCR were deleted in vivo, whereas CD4
+
 T cells 
with the m33 TCR persisted, and were capable of mediating an anti-tumor response [30]. Here 
we show that the higher affinity TCR m33 was superior to the lower affinity 2C TCR in 
mediating effective destruction of B16 melanomas by CD4
+
 T cells. While the 2C-transduced 
CD4
+
 T cells mediated an effect against antigen-bearing tumors, antigen loss variants were 
responsible for reoccurrence in every case. The m33-transduced CD4
+
 T cells not only mediated 
a stronger response, as measured by delayed tumor growth and/or elimination of antigen loss 
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variants, but some mice also generated a long-term response. Furthermore, CD4
+
 T cells in these 
mice persisted and they mediated an antigen-specific memory response against the B16-SIY 
melanomas. These results indicate that there are benefits to using TCRs with affinities that are 
higher than current TCRs (e.g. DMF5) in adoptive CD4
+
 T cell therapies. 
 
3.2 Materials and Methods 
 
Mice and tumor cell lines 
Experiments were performed with C57BL/6 and C57BL/6 Rag1
-/-
 mice, 2-5 months of 
age, purchased from The Jackson Laboratory (Bar Harbor, ME). Mice were maintained as 
colonies and housed in the animal facilities at the University of Illinois. All animal studies were 
approved by the Institutional Animal Care and Use Committee at the University of Illinois. 
Murine melanoma B16-F10 cells were purchased from ATCC (Manassa, VA). B16-SIY was 
derived from B16-F10 cells engineered to express green fluorescent protein (GFP) as a fusion 
protein with SIYRYYGL (SIY) [54,55]. Cell lines were cultured in complete RPMI 1640 
medium containing 5 mM HEPES, 10% fetal bovine serum (FBS), 1.3 mM L-glutamine, 50 µM 
2-ME, penicillin, and streptomycin at 37°C and 5% CO2. 
 
Interferon gamma treatment and flow cytometry of melanoma cells 
Melanoma cells were cultured at a density of 7 x 10
5
 cells per well (6-well plate), with or 
without 10 ng/mL interferon gamma (IFN-γ, eBioscience) for 24 hours. Cells were stained with 
anti-K
b
 (B8.24.3 monoclonal antibody) or soluble biotinylated single-chain TCR m67 to detect 
SIY peptide bound to H2-K
b
 on the surface of tumor cells [32]. After 1 hr, cells were washed and 
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streptavidin-allophycocyanin (Invitrogen) was added for 30 min. Cells were analyzed on an 
Accuri C6 Flow Cytometer. 
 
51
Chromium T cell killing assay 
Target cells labeled with 
51
Cr (150 µl of 2 mCi/mL) were incubated with mock, 2C WT 
or m33 TCR-transduced CD4
+
 T cells at 5:1 and 20:1 effector to target (E:T) ratios for 4 hrs. 
Supernatants were assayed using a Beckman gamma counter; specific lysis was calculated using 
the formula: ((sample chromium counts – spontaneous chromium release)/(maximum chromium 
counts – spontaneous chromium release)) x 100. Chromium release from B16-SIY melanoma 
cells incubated with mock CD4
+
 T cells was used to calculate percent specific B16-SIY cell 
lysis. 
 
Melanoma tumor model and T cell transfer 
B16-F10 or B16-SIY melanoma cells were harvested and washed twice with Hanks 
Balanced Salt Solution (HBSS, Cellgro Mediatech Inc). Shaved mice received 1-1.5 x 10
6
 tumor 
cells subcutaneously into the right flank (unilateral tumor) or right and left flank (bilateral 
tumors) of Rag1
-/-
 mice under isoflurane (Baxter) inhalation anesthesia. For adoptive T cell 
transfer, an average of 7 x 10
6
 mock and TCR-transduced CD4
+
 or CD8
+
 T cells harvested from 
24-well plates and washed twice with HBSS, were injected in the tail vein of mice either 5 days 
or 10 days (established tumor model) following tumor inoculation. Tumor growth was monitored 
by measuring tumor length and width with a caliper every two days. Tumor volume was 
estimated as (length × (width
2
))/2. 
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Preparation of melanoma tumors ex vivo 
For isolation of single-cell suspensions to detect antigen-loss variants, implanted B16-
SIY melanoma tumors were harvested, sectioned, and incubated with 300 Collagenase Digestion 
U/mL (Sigma-Aldrich) and 1 mg/mL Dispase (Roche) for 40 minutes at 37°C. After incubation, 
0.002 MU/mL DNase (Calbiochem) was added for further dissociation using gentleMACS 
Dissociator (Miltenyi Biotec). Cell suspensions were pipetted through 100 µm filters and 
centrifuged at 300 xg for 10 minutes. Single-cell suspensions were cultured for 6-7 days, treated 
with IFN-γ and stained with TCR m67. 
 
Analysis of lymphocyte cell surface phenotypes 
Single-cell suspensions from lymph nodes or spleens were dual-stained with 
AlexaFluor647-conjugated rat anti mouse CD4 Ab (Clone RM4-5, BD Pharmingen) in 
combination with either PE-conjugated rat anti-mouse CD62L Ab (Clone MEL-14, BD 
Pharmingen), AlexaFluor488-conjugated rat anti-mouse CD127 Ab (Clone SB/199, BD 
Pharmingen), or PE-conjugated mouse anti-mouse Vβ8.1/8.2 Ab (Clone MR5-2, BD 
Pharmingen). For isotype controls, cells were stained with PE-conjugated rat IgG2a, 
AlexaFluor488-conjugated rat IgG2b, or PE-conjugated mouse IgG2a. After washing, cells were 
analyzed by flow cytometry (Accuri C6). 
 
TCR gene retroviral transduction of primary murine T cells 
Platinum-E (Plat-E) retroviral packaging cells were transfected with 2C TCR or m33 
TCR genes cloned into the pMP71 vector (from myeloproliferative sarcoma virus, MPSV) as 
described [30]. Viral supernatants were harvested 48 hours after transfection, filtered with a 0.45 
71 
 
µm syringe filter, and 50 µl of Lipofectamine 2000 added per 6 mL of viral supernatant. For 
transductions, CD8
+
 or CD4
+
 T splenocytes from C57BL/6 mice were negatively selected by 
magnetic sorting using the Mouse CD8α+ or CD4+ T Cell Isolation Kit II (MACS Miltenyi 
Biotec, Germany), and activated by incubation with anti-CD3/anti-CD28 mouse T-activator 
Dynabeads (Invitrogen) and 30 U of recombinant mouse IL-2 (Roche, Germany) for 24 hours. 
Prior to transduction, Dynabeads were magnetically removed from activated CD8
+
 or CD4
+
 T 
cells and cells were transferred into a 24-well plate coated with Retronectin at 15 µg/mL 
(Takara, Japan). In each well, 10
6
 T cells in 1mL of T cell media were mixed with 1mL sterile 
viral supernatant and 60 U of recombinant murine IL-2. Plates were centrifuged at 2000 rpm at 
30°C for 1 h. 
 
Statistical analyses 
GraphPad Prism software was used for all statistical analyses. Percent specific lysis was 
analyzed by t-test and comparison of survival curves by log-rank (Mantel-Cox) test. Tumor 
volume measurements were compared using a one-way analysis of variance followed by 
comparisons of individual treatments using the Bonferroni correction for multiple comparisons. 
Transduced CD4
+
 and CD8
+
 T cells were compared with their respective mock transductants. 
For tumor volume at 26 days, a planned comparison of wild-type 2C CD4
+
 and m33 CD4
+
 was 
analyzed by a t-test. Individual p values are given in figure captions. 
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3.3 Results 
 
IFN-γ treatment is required for detectable surface expression of SIY/Kb complexes on B16-SIY 
melanoma cells 
Our recent study showed that the MC57-SIY tumor could be rejected by CD4
+ 
T cells 
transduced with the high-affinity TCR called m33 [30]. We have shown that this tumor expresses 
constitutively high levels of SIY/K
b
 (SIYRYYGL), as measured with a soluble high-affinity 
TCR called m67 [32]. To explore a tumor system with lower antigen presentation levels, we 
elected to use the B16 melanoma model, as the SIY-transfected B16 cells did not express SIY/K
b
 
at constitutive levels detectable by the m67 TCR (i.e. B16-SIY expressed less than 1000 SIY/K
b
 
molecules per cell) (Fig. 3.1a). To determine if detectable levels of SIY/K
b
 could be induced by 
treatment with IFN-γ, we cultured B16 F10 (the parental cell line) and B16-SIY cells overnight 
with 10 ng/ml IFN-γ. Higher surface expression levels of Kb were observed on both cell lines but 
induction of SIY/K
b
 expression was observed only with B16-SIY. These findings demonstrate 
that although B16-SIY cells have low constitutive levels of SIY/K
b
, increased levels can be 
induced by IFN-γ treatment, as might be achieved in an inflammatory setting in vivo. 
 
Lysis of IFN-γ treated B16-SIY cells by 2C and m33-transduced CD4+ T cells 
Recent evidence suggests that CD4
+
 T cells can directly kill tumor cells [11,12]. 
Accordingly, we evaluated the ability of untreated and IFN-γ-treated B16-SIY cells to be lysed 
by 2C or m33 TCRs transduced into activated CD4
+
 polyclonal T cells (Fig. 3.1b). Untreated 
B16-SIY melanoma cells were killed poorly by both 2C and m33-transduced CD4
+
 T cells, 
whereas IFN-γ treatment resulted in B16-SIY lysis by both effector cells. Significantly enhanced 
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killing was observed with the high-affinity m33 TCR-transduced T cells at both E:T cell ratios 
tested. These observations suggest that IFN-γ stimulation at the site of a B16-SIY tumor will be 
important to raise the surface levels of the SIY/K
b
 for effective killing. Other studies have shown 
a critical role for IFN-γ in tumor destruction [33,34]. These results also show that m33-
transduced CD4
+
 T cells may provide enhanced recognition and activation, probably due to its 
higher affinity and ability to mediate signaling in a CD8-independent mode. 
 
Antigen-specific destruction of B16 melanoma tumors is mediated most effectively by CD4
+
 T 
cells transduced with high affinity m33 TCR 
To compare the effectiveness of 2C and m33-transduced T cells in vivo, we used the B16-
SIY cancer cells (1 x 10
6
) as a transplanted, subcutaneous tumor model in Rag1
-/-
 mice. Five 
days after tumor transplantation, when the tumors were palpable (~100 mm
3
), adoptive T cell 
transfer was performed. Purified primary T cells from C57BL/6 splenocytes were activated ex 
vivo with anti-CD3/anti-CD28-coated beads and IL-2. The purified CD8
+
 or CD4
+
 T cell 
populations were mock-transduced, transduced with wild type affinity 2C TCR (Kd = 30 µM) or 
transduced with the high affinity m33 TCR (Kd = 30 nM). The levels of 2C and m33 TCRs on 
the transduced populations were similar, as judged by staining with an anti-Vβ8 antibody (data 
not shown). The efficiency of T cell transduction in the experiments ranged from 34 to 59%, as 
judged by the fraction of T cells positive above the mock-transduced controls. 
Mice treated with saline or m33-transduced CD8
+
 T cells showed uniformly rapid tumor 
growth (Fig. 3.2a) likely due to the disappearance of m33 CD8
+
 T cells [30]. After several days 
of rapid growth, mock-transduced CD8
+
 T cells were able to delay tumor growth in several mice. 
This result was SIY-dependent as the parental line B16 F10 was not controlled by CD8
+
 T cells 
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(data not shown). These results are consistent with emergence of some CD8
+
 T cells in the 
polyclonal population that recognize SIY/K
b
 [2,35]. However, this tumor control was distinctly 
less effective than 2C-transduced CD8
+
 T cells (Fig. 3.2a). The 2C-transduced CD8
+
 T cell 
population mediated rapid reduction in tumor growth but could not prevent relapse. 
Mock-transduced CD4
+
 T cells, unlike mock-transduced CD8
+
 cells, did not show the 
same ability to delay growth of B16-SIY tumors (Fig. 3.2b); this is consistent with the notion 
that CD8
+
 T cells, but not CD4
+
 T cells, express among their native repertoire, TCRs with class 
I-restricted tumor-antigen specificity. Interestingly, both the 2C and m33-transduced CD4
+ 
populations were capable of significant tumor control (Fig. 3.2b), despite 2C TCR’s relatively 
low affinity. However, m33 CD4
+
 T cells were more effective at delaying progression of B16-
SIY tumors, and two of the mice showed no tumor recurrence even after 60 days. This suggests 
the importance of TCR affinity in redirected CD4
+
 effector T cells. To directly compare the 
adoptive T cell populations, cohorts were analyzed for average tumor size at a single time-point 
(day 26). This analysis (Fig. 3.2c) highlighted that high-affinity m33 CD4
+
 T cells were the most 
effective at controlling tumor growth. 
 
Recurrence of B16-SIY tumors is a result of selection of antigen loss variants 
Despite the tumor destruction and survival benefit observed with TCR-transduced T cells, 
most of the B16-SIY tumors ultimately escaped immune attack and recurred. To examine why 
tumor progression eventually occurred, tumors were excised, cultured, and analyzed for antigen 
loss variants (ALVs) using the high-affinity TCR m67 as a specific probe. All tumor samples 
isolated from saline-treated or mock-transduced CD4
+
 T cell-treated mice expressed uniform 
levels of K
b
 and SIY/K
b
, similar to that of the cultured B16-SIY cell line (Fig. 3.3). In contrast, 
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all tumor samples isolated from mice with tumor regression, and then progression, after adoptive 
cell therapies with 2C WT or m33-transduced T cells retained high K
b
 surface expression but lost 
SIY/K
b
 expression. Thus, as was often the case in previous studies (e.g. ref [36]), ALVs 
accounted for the inability to completely eradicate tumors. Interestingly, given the delayed 
progression of tumors treated with m33 CD4
+
 populations (and complete eradication in two 
mice), these T cells appear to have provided enhanced destruction, or delayed growth of ALVs, 
perhaps through recognition of cross-presented SIY/K
b
 on stroma [2]. 
 
m33 CD4
+ 
T cell-treated long-term survivor mice exhibit persistence of SIY-specific effector 
memory T cells 
Adoptive transfer of m33 CD4
+
 T cells, but not 2C CD4
+
 T cells, led to rejection of B16-
SIY tumors in some mice. This provided an opportunity to investigate in vivo T cell persistence 
and prolonged immune response against B16 melanoma cells. A long-term survivor mouse 
completely rejected a B16-SIY cancer cell inoculum after a single transfer of m33 CD4
+
 T cells 
65 days earlier (Fig. 3.4a). Thus, even in the absence of additional T cell transfer, tumor growth 
control was maintained over two weeks compared to rapidly growing melanoma tumors in 
untreated control mice. Prevention of tumor outgrowth indicates prolonged anti-tumor activity 
against B16-SIY cells. 
To assess whether the immune response against B16-SIY tumor re-challenge was antigen 
specific, another long-term survivor mouse was bilaterally implanted with B16 F10 and B16-SIY 
at 49 days post m33 CD4
+
 T cell transfer. This long-term survivor showed uncontrolled B16 F10 
tumor growth while selectively rejecting B16-SIY cells. Both B16 F10 and B16-SIY tumors 
grew rapidly in all untreated control mice (Fig. 3.4b, 3.4c). Lack of an anti-tumor response 
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against the parental line B16 F10 suggests that SIY-specific immunity was generated against 
B16-SIY melanoma cells. 
 Lymph nodes (LNs) and spleens were harvested from long-term survivor mice for 
phenotypic characterization of T cells by flow cytometry. Analysis of the lymphoid tissue 
revealed long-term persistence of CD4
+
 T cells over 80 days after m33 CD4
+
 T cell transfer (Fig. 
3.5a). These CD4
+
 cells were predominantly CD127
high
 and CD62L
low
, a phenotype associated 
with peripheral effector memory T cells [37-39]. Additionally, we confirmed that the transduced 
m33 TCR was expressed by Vβ8 staining of the CD4+ cells (Fig. 3.5b). Thus, persistence of the 
m33, Vβ8+ effector memory T cells correlated with the results observed following tumor re-
challenge. Together, these findings demonstrate that primary CD4
+
 T cells transduced with high-
affinity TCRs can persist in vivo and exert effective anti-tumor protective immunity against B16-
SIY melanoma, despite the presence of ALVs among the original tumor population. 
 
T cell therapy with CD4
+
 cells expressing high affinity m33 TCR lead to enhanced survival of 
mice with large, established tumors 
In our initial studies, tumor-bearing mice were adoptively transferred TCR-transduced T 
cells 5 days following tumor implant, when tumors measured approximately 100 mm
3
. We 
sought to investigate the anti-tumor effectiveness of TCR-transduced cells against more 
established tumors. Experimental studies with larger and more established tumors provide an 
improved clinical cancer model in aspects of cellular heterogeneity and tumor vasculature 
[40,41]. In this tumor model, cell transfer of T cells was performed 10 days post tumor implant, 
when tumors averaged 500 mm
3
 in size (1 cm in diameter). T cell therapy with both 2C and m33 
CD4
+
 T cell populations resulted in enhanced survival despite increased tumor burden at time of 
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T cell treatment (Fig. 3.6a). Tumors initially continued to grow for several days after adoptive 
transfer of T cells. However, within 12 days post T cell transfer, tumor size was markedly 
decreased in both treatment groups compared to mock CD4
+
 treated mice which succumb to their 
tumor within 18 days post transfer of T cells (Fig. 3.6b). 
Importantly, again in the model with more established tumors, high-affinity m33 TCR-
transduced cells yielded significantly better survival than wild-type 2C TCR-transduced T cell 
treatment (Fig. 3.6a) and even led to a dramatic tumor shrinkage in one mouse from close to 
criteria for euthanasia with a tumor size of 2500 mm
3
 to no measurable mass lasting a period of 6 
days. Although tumor size was greatly reduced, all tumors eventually recurred. Ex vivo 
phenotype of recurring tumors again confirmed that tumor outgrowth was a result of ALVs, 
which retained expression of K
b
 but lost surface expression of SIY/K
b
 complexes (Fig. 3.6c). 
 
3.4 Discussion 
 
The experimental design described here, with a model tumor antigen (SIY), addresses the 
question whether there is an optimal affinity for TCRs that can redirect the activities of CD4
+
 
and CD8
+
 T cells against a class I antigen on tumors. Our salient findings are that: 1) lower, 
wild-type affinity TCR within the range found in normal CD8
+
 T cells (Kd of 30 µM) was 
capable of mediating effective CD8
+
 T cell responses in the transduced T cell system, in line 
with many previous studies that used transgenic 2C CD8
+
 T cells, 2) TCR-transduced CD4
+
 T 
cells exhibited both direct killing of the class I-positive tumors in vitro and effective control of 
tumors in vivo, and 3) an in vitro engineered TCR, m33, with high (nanomolar) affinity mediated 
more effective tumor targeting by CD4
+
 T cells than the wild-type 2C TCR. 
78 
 
Compared to results with CD8
+
 T cells, there was improved tumor targeting efficacy 
using CD4
+
 T cells transduced with the high-affinity TCR. Accordingly, CD4
+
 cells expressing 
the m33 TCR (Kd of 30 nM) exhibited significant improvements in tumor destruction and longer 
survival in comparison to wild-type affinity 2C TCR. Impressively, this included treatment of 
larger, established tumors of up to 2500 mm
3
 in one case. By analogy, the second generation 
MART-1 specific TCR called DMF5 (Kd = 40 µM) was chosen because it exhibited greater 
activity than the TCR DMF4 in CD4
+
 T cells in various assays in vitro [27,22,42]. The improved 
efficacy of CD4
+
 T cells may be associated with the production of cytokines such as IFN-γ, 
which clearly has a dramatic effect on the expression of the SIY/K
b
 antigen. These results are in 
line with recent observations by Gajewski and colleagues, where IFN-γ mediated effector 
function of CD4
+
 cells was associated with B16 melanoma tumor growth control and reduced 
tumor vasculature [43]. Earlier studies using the B16-OVA system, and CD8
+
 OT-1 TCR 
transgenic T cells, had shown an effect of IFN-γ on host cells, in addition to a direct effect of 
B16-tumors [44]. Thus, the enhanced effect of CD4
+
 T cells in our study could also be due to 
indirect IFN-γ dependent-mechanisms [9-12]. 
Most previous studies with tumor-reactive T cells have described their TCRs in the 
context of high or low “avidity”; this is in part because the actual monomeric binding constants 
(Kd values) of TCRs are rarely measured. In the context of many studies with T cells, the term 
“avidity” has generally referred to the notion that one T cell yielded more effective activity 
(“higher avidity”) against the same antigen compared to another clone (“lower avidity”). It is 
useful to consider the 2C system in this context. The 2C TCR showed some activity in CD4
+
 T 
cells, and by this criterion it would be considered “high avidity” in comparison to a SIY-specific 
TCR that showed no activity in CD4
+
 T cells. However, 2C TCR is clearly less active in CD4
+
 T 
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cells than the m33 TCR. Thus, the term high avidity is a relative term, requiring comparison of 
multiple different TCRs against the same antigenic peptide. We suggest that TCRs derived from 
typical TILs or ex vivo generated T cells (wild-type TCRs) may not yield the affinities that can 
mediate more effective activities, as shown here for m33. These affinities may only be achieved 
by directed evolution in vitro (as with m33), or by other strategies that select for TCRs that bind 
to class I MHC ligands in the absence of the CD8 co-receptor. Nevertheless, it is clear that 
driving the affinity too high (e.g. picomolar), may also yield self-peptide reactivities even in the 
CD4
+
 T cell population [18], and thus there will be an optimal range of affinities. 
Tumor specific CD4
+
 T cells have been demonstrated to have a direct role in mediating 
tumor regression. In a clinical study, one patient experienced complete tumor remission 
following infusion of melanoma antigen-specific CD4
+
 T cells [45]. The possible limitations to 
the use of TCR-gene modified CD4
+
 cells for ACT include the downregulation of MHC class I 
levels, and the possible need for CD8 co-receptor to recognize lower levels of antigen. Antigen 
loss variants (ALVs) are also a major problem associated with adoptive T cell therapies that 
target a single antigen [36]. In particular with melanoma, T cell therapy exerts a strong selective 
pressure on tumor cells resulting in the emergence of ALVs in experimental mice as well as 
clinically [46,47]. To some extent at least, higher affinity TCRs may mitigate each of these 
issues. However, it remains to be seen if the affinity of TCRs against class I MHC that drive 
particular CD4
+
 T cell subsets (TH1, TH2, TH17, Treg or memory versus effector) will differ. These 
studies can now be approached with 2C, m33, and our collection of affinity variants of these 
TCRs [20]. 
It is worth considering why some previous studies have described the complete 
elimination of tumors, including ALVs, in mice that received TCR transgenic T cells, as opposed 
80 
 
to TCR-transduced T cells. In the most directly related study with the 2C system, it was shown 
that large, established MC57-SIY-hi tumors could be completely eliminated by transfer of 2C 
TCR transgenic CD8
+
 T cells [48]. However, MC57-SIY-lo tumors could not be completely 
eliminated, due to ALVs and reduced levels of stroma cross-presentation [48,32,49]. Other 
studies, with MC57-gp33-hi and MC57-gp33-lo tumors, found similar results using P14 TCR 
transgenic CD8
+
 T cells [50]. Thus, antigen levels clearly are one factor in determining whether 
ALVs can be destroyed, and in this respect, the B16-SIY tumors express no detectable levels of 
SIY/K
b
 unless they are induced with IFN-γ. In contrast, the MC57 tumors constitutively express 
detectable levels the SIY/K
b
 antigen [32]. 
In addition to antigen levels, there are other factors that could contribute to the outgrowth 
of ALVs as observed in previous reports and in the present study. There is considerable 
variability in the number of tumor cells used in the different studies, and the timing of adoptive T 
cell transfers, even in the B16 melanoma models. Other studies have injected 5x10
4
 or 10
5
 B16 
tumor cells [44,50,47], whereas the mice in our study received 10
6
 B16-SIY tumor cells. Other 
studies transferred T cells one to seven days following tumor injection [44,50,47], while our 
study injected T cells either five or ten days after B16-SIY injection. Given the rapid growth rate 
of B16 tumors, clearly the size of the tumor at time of T cell treatment will be related to the 
likelihood of ALV outgrowth. 
Finally, the T cell population(s) used for treatment will also impact the ability to control 
tumor growth and ALV destruction. A previous study showed that a B16-gp33 tumor was 
effectively controlled, without ALVs, by P14 TCR-transgenic CD8
+
 T cells, but not by P14 
TCR-transduced T cells [50]. These effects could be related to slightly lower transduced TCR 
levels (compared to transgenic T cells), due to mis-pairing with endogenous TCR chains [51]. 
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Higher affinity TCRs require fewer molecules per T cell in order to mediate activity, and they 
can do so at lower antigen levels [52], which could in part explain why m33 exhibits improved 
activity compared to 2C. It should also be noted that in our studies, the recipient T cells are 
polyclonal CD4
+
 and CD8
+
 T cells from C57Bl/6 mice, not activated TCR transgenic T cells 
(e.g. OT-1) [50,30]. Furthermore, recipient T cells in our study have undergone in vitro 
activation with anti-CD3/CD28 antibody coated beads, whereas most transgenic T cells studies 
used T cells activated with the cognate peptide [44,50,47]. It is unclear whether different 
methods of activation lead to different levels of function (e.g. cytokine release, persistence, 
activation-induced cell death) that might impact efficacy. Polyclonal T cells may also contain 
subpopulations of regulatory cells [53] that contribute ultimately to effects on tumor control. 
In summary, there are many complex factors that need to be examined to fully understand 
what the optimal T cell format will be for clinical adoptive T cell therapies. We provide evidence 
that CD4
+
 T cell therapy with high affinity TCR resulted in tumor rejection; in some cases the 
rejection resulted in long-term survivor mice exhibiting SIY-specific tumor responses against 
B16-SIY tumor re-challenge. We also observed CD62Llow and CD127high TCR-transduced 
effector memory T cells. In a well-established tumor model with tumors measuring on average 1 
cm in diameter, m33-expressing CD4
+
 cells displayed strong anti-tumor effects. Adoptive 
transfer of m33 CD4
+
 cells in this model displayed significant tumor destruction and improved 
survival compared to 2C CD4
+
 treatment. High affinity TCR-transduced CD4
+
 cells not only 
provide antigen-specific effective immune responses in vivo but they also persist long-term after 
tumor regression. Together, these findings provide evidence of the advantages of using TCRs 
with high affinity, especially the possibility of redirecting both CD4
+
 and CD8
+
 T cells to target 
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the same MHC class I-restricted tumor antigens. This is especially interesting in the light of the 
need for having both CD8 and CD4 antigens on the same cell [2]. 
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CHAPTER FOUR: 
 
GRAFT-VERSUS-HOST RESPONSES ASSOCIATED WITH ADOPTIVE TRANSFER 
OF TCR-TRANSDUCED T CELLS 
 
4.1 Introduction 
 
 Immunotherapies, such as adoptive T cell therapy, are being examined for their antitumor 
immune effects against malignant cancers. T cell therapy, in particular, has been best illustrated 
through preclinical studies and clinical trials of adoptive cell therapy (ACT) for treatment of 
melanoma [1-3]. The positive response rates achieved with treatment of melanoma suggest that 
ACT may provide an effective treatment strategy to enhance the recognition and ultimate 
destruction of neoplastic cells. Likewise, hematological malignancies like leukemia, can be 
targeted with leukemia-reactive cytotoxic T lymphocytes (CTLs) isolated from donor patients 
[4]. Although a promising approach, isolating and expanding tumor-reactive T cells from 
patients is very challenging and not a feasible option for all patients. A strategy to circumvent 
this limitation can be achieved through gene-modified T lymphocytes expressing antigen-
specific T cell receptors (TCRs). 
 The therapeutic potential of TCR gene therapy was highlighted in a clinical trial led by 
Morgan and colleagues [5]. Metastatic melanoma patients were adoptively transferred MART-1 
TCR-engineered T cells. Two patients, out of seventeen, demonstrated sustained cancer 
regression up to 21 months after treatment. Similarly, T cells’ antitumor activity can be 
harnessed against leukemia with TCR-transduced CD8
+
 T cells [6]. Despite these successes with 
ACT, there are safety concerns associated with TCR gene therapy. Mispairing of endogenous 
TCR chains with exogenous TCR chains may generate new TCRs with specificities for host 
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tissue. These host-reactive TCRs may result in graft-versus-host responses. Other safety 
concerns are related to transduction of high affinity TCRs into CD8
+
 T cells which can lead to an 
increased reactivity of these T cells with self-antigens. Based on work by Holler at al., 
transduction of high affinity variants of the 2C TCR (30 μM), such as m33 TCR (20 nM), into 
CD8
+
 T cells can lead to increased reactivity against self-antigens [7]. Reactivity with self-
antigens seems to be facilitated by the CD8 co-receptor since high affinity TCRs transduced into 
cells lacking the CD8 co-receptor show less reactivity against self-antigens (e.g. dEV8-K
b
 in the 
2C system) [8]. 
  Graft-versus-host reactions have been greatly associated with hematopoietic stem cell 
transplantation (SCT) for the treatment of cancers such as leukemia [9-11]. SCT is an alternative 
curative therapy to eradicate malignant cells, where the patient’s own immune system is first 
destroyed with radiation or chemotherapy prior to SCT. Unless T cell depleted, SCT donor 
allografts contain alloreactive T cells. In leukemia, these alloreactive cells mediate beneficial 
graft-versus-leukemia (GVL) responses but these donor T cells can also result in graft-versus-
host disease (GVHD) [12]. 
 In GVHD, an immune attack is directed by the donor cells against normal host tissue. 
Clinical presentation includes both an acute form of GVHD (reaction within 100 days of graft 
transfusion) and a chronic form (> 100 days after graft transfusion). Acute GVHD is generally 
accompanied by tissue damage of the skin, liver, and the gastrointestinal tract while chronic 
GVHD targets a wide array of organs and can bear similarities with autoimmune disorders. For 
prevention and treatment of GVHD, immunosuppressive drugs can be administered alone or in 
combination with other therapies such as monoclonal antibodies. The current standard of care for 
GVHD prevention after SCT includes combined administration of tacrolimus and methotrexate 
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[13]. Despite availability of treatment, severe GVHD remains a major cause of morbidity and 
mortality following SCT. For this reason, new approaches to prevent or suppress GVHD need to 
be developed.  
 In our strategy of utilizing genetically engineered TCRs introduced into T lymphocytes, 
we have encountered GVHD. Some mice receiving TCR-transduced T cells developed GVHD 
several weeks after adoptive T cell transfer. Manifestation of GVHD was not linked to TCR 
affinity (2C-wild type vs. m33-high affinity) or specific tumor model (melanoma vs. glioma). 
Here, we present the clinical signs, physical GVHD presentation, and GVHD-associated 
histopathology observed in these mice. Our goal is to dissect these responses to better understand 
the mechanisms and factors involved in the in vivo interactions between the transferred T cell 
populations and the targeted host tissue.   
 
4.2 Materials and Methods 
 
Mice and cell lines 
C57BL/6 and RAG1
-/-
 mice were originally purchased from The Jackson Laboratory (Bar 
Harbor, ME) and maintained as colonies in the animal facilities at the University of Illinois. We 
utilized immunodeficient RAG1
-/-
 mice (lacking B and T cells) as a model representing a similar 
immunological state as that of patients in the clinical setting following radiation therapy prior to 
adoptive cell therapy (ACT). Mice were 2-5 months of age at the time of experiments and all of 
the animal studies were approved by the Institutional Animal Care and Use Committee at the 
University of Illinois at Urbana-Champaign. The B16-SIY murine melanoma cell line was a 
generous gift from Dr. Thomas Gajewski (University of Chicago, IL). B16-SIY cancer cells were 
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derived by retroviral transduction of B16 F10 cells with a fusion protein of the K
b
-binding 
peptide SIY and enhanced green fluorescent protein (EGFP) [14]. The murine glioma cell line 
GL261-SIY was derived by retroviral transduction of GL261 parental cells with a fusion protein 
of the K
b
-binding peptide SIY with EGFP in our lab (University of Illinois, Urbana-Champaign). 
All cancer cell lines are syngeneic to the C57BL/6 background and were grown in complete 
RPMI 1640 media (RPMI 1640 supplemented with 5 mM HEPES, 10% Fetal Bovine Serum 
(FBS), 1.3 mM L-glutamine, 50 pM 2-ME, penicillin, and streptomycin) at 37°C in 5% CO2 in a 
humidified incubator. 
 
Subcutaneous (s.c.) melanoma tumor cell implant and T cell transfer 
Murine melanoma cells were trypsinized, collected, and washed twice with sterile Hank’s 
Balanced Salt Solution (HBSS). RAG1
-/-
 mice were administered 1.1 x 10
6
 B16-SIY cells/150 μl 
HBSS on the right flank under isoflurane (Baxter) inhalation anesthesia. For adoptive T cell 
transfer, an average of 7 x 10
6
 mock and TCR-transduced CD4
+
 or CD8
+
 T cells harvested from 
24-well plates and washed twice with HBSS, were injected in the tail vein of mice 5 days 
following tumor cell inoculation. Tumor growth and volume was monitored by measuring the 
tumors’ length and width with a caliper every two days. Calculation of tumor volume was 
analyzed as (length × (width
2
))/2. 
 
Intracranial (i.c.) melanoma tumor cell implant and T cell transfer 
Murine GL261-SIY glioma cells were trypsinized, collected, and washed twice with 
sterile HBSS, and stereotaxically infused into the brain of RAG1
-/-
 mice. 8 x 10
4
 glioma cells 
were infused in 500 nl into the right ventral striatum (from bregma: 0.5 mm rostral; 2.5 mm 
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lateral; 4 mm ventral). For adoptive T cell transfer, TCR-transduced CD8
+
 and CD4
+
 T cells 
were harvested from 24-well plates and washed twice with HBSS. 5 x 10
6
 T cells per mouse 
were administered intravenously (i.v.) 13 days post-tumor cell implant. 
 
Activation and retroviral transduction of primary T cells 
T cells were obtained from spleens of C57BL/6 mice and prepared into a single-cell 
suspension. Erythrocytes were lysed with ammonium chloride buffer and CD8
+
 and CD4
+
 T cells 
isolated by magnetic sorting using the Mouse CD8α+ or CD4+ T Cell Isolation Kit II (MACS 
Miltenyi Biotec, Germany). T cell transduction was performed as described in Soto et al. (Cancer 
Immunology Immunotherapy 2012, manuscript in press). Briefly, 1 x 10
6 
T cells per well were 
activated with anti-CD3 and anti-CD28 coated beads (Dynabeads, Invitrogen) and 30 U of 
recombinant mouse IL-2 (Roche) in a 24 well plate for 24 h. Following activation, the beads 
were magnetically removed and cells transferred into a 24-well plate coated with Retronectin at 
15 μg/mL (Takara, Japan). In each well, 1 x 106 T cells in 1mL of T cell media were mixed with 
60U of recombinant murine IL-2 and 1 mL sterile 2C or m33 TCR viral supernatant. The plate 
was centrifuged at 2,000 rpm at 30°C for 1 h.  
 
Immunohistochemistry 
Rat anti-mouse CD3 antibody was purchased from eBioscience, DyLight 594-conjugated 
AffiniPure F(ab')2 Fragment donkey anti-rat IgG (H + L) was purchased from Jackson 
ImmunoResearch Laboratories, and 4,6-diamidino-2-phenylindole (DAPI) was obtained from 
Invitrogen. Mice were sacrificed when they reached criteria for euthanasia. Ear tissue was 
embedded in OCT medium and frozen. Staining was performed on 8-micron cryostat sections, 
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mildly fixed by incubation in 95% ethanol at -20°C for 20 min and endogenous peroxide 
quenched by incubation in 0.3% H2O2 in methanol for 5 min. Blocking was done with 
SuperBlock (ThermoScientific) and 5% normal serum of the species of the secondary antibody. 
Anti CD3 primary antibody was applied at 5–10 μg/ml for 24 h in blocking solution 
overnight. Tissue sections were incubated with Dylight 594 secondary antibody for 45 min and 
counterstained with 4,6-diamidino-2-phenylindole (DAPI, Invitrogen).  
 
Hematoxylin and eosin histopathology 
 Internal organs and skin of mice were fixed in 10% buffered formalin, trimmed into 
cassettes, and submitted to the University of Illinois Veterinary Diagnostic Laboratory to be 
paraffinized, sectioned (6 μm thickness), stained with hematoxylin and eosin (H&E).  Tissue 
sections were then evaluated by A.L.M. using light microscopy. 
 
Flow Cytometry Analysis of Transduced T Cells 
 
Seventy two hours after the first transduction, TCR-transduced T cells were analyzed by 
flow cytometry for expression of the CD8 co-receptor, CD4 co-receptor, and TCR Vβ levels. T 
cells were collected from the 24-well dish and washed once with 0.5% PBS/BSA. Mock 
transduced, 2C TCR transduced, and m33 TCR transduced T cells were incubated with 
Phycoerythrin (PE) labeled anti mouse CD8α (BD Pharmigen) and biotin mouse anti mouse 
Vβ8.1/8.2 antibodies (BD Pharmigen) at a concentration of 10 μg/ml for 1 hr at 4°C. After 
washing the cells twice with 0.5% PBS/BSA, Strepavidin-647 (Invitrogen) was added at 10 
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μg/ml to anti Vβ stained T cells and incubated for 45 minutes at 4°C. T cells were washed twice 
with 0.5% PBS/BSA and analyzed on Accuri C6 Flow Cytometer. 
 
4.3 Results 
 
GVHD responses following transfer of TCR-transduced T cells 
 Adoptive cell transfer (ACT) studies performed by our laboratory involved introducing 
gene-modified TCRs against tumor antigens into primary murine CD8
+
 and CD4
+
 T cells. 
Several weeks post-T cell transfer, a number of mice developed progressive decreased motility 
and activity, skin lesions involving the eye, ears and tail, hunched posture, and diarrhea. These 
clinical signs are associated with graft-versus-host disease (GVHD) development which is 
induced by donor T cell-mediated immune responses directed against normal host tissue. These 
clinical signs suggest that tumor-specific TCR-transduced T cells administered into tumor-
bearing mice play a key role in the GVHD pathogenesis observed. Seven long-term survival 
studies of adoptive immunotherapy of melanoma and glioma were performed (Table 4.1). Of 
these, three studies were noted to include RAG1
-/-
 mice displaying GVHD clinical signs 
following transfer of TCR-transduced T cells. In all seven studies, primary murine lymphocytes 
were isolated from C57BL/5 mice, activated and retrovirally transduced with the SIY-specific 
2C TCR or its high-affinity version, m33 TCR. All of the T cells were administered through tail 
vein injection and regulatory T cells (CD25
+
) were not depleted from the T cell population. The 
number of adoptively transferred cells ranged from an average of 5.85 x 10
6
 to 8 x 10
6 
T cells per 
mouse. Experimental groups included T cells transduced with 2C TCR, 2C TCR Library, m33 
TCR, m33 TCR Library, as well as mock transduced T cells. ACT treatment of mice was 
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primarily with only CD8
+
 or CD4
+
 T cells except in two studies where we investigated a 
combination strategy using both CD8
+
 and CD4
+
 TCR-transduced cells adoptively transferred 
together. In one of the two studies, equal numbers (1:1) of CD8
+
 and CD4
+
 cells were initially 
mixed and transduced together with one TCR or TCR-specific Library. Whereas the second 
study examined CD8
+
 or CD4
+
 T cells separately transduced with 2C and m33 TCR, 
respectively.  
 GVHD responses appear to be primarily associated with adoptive transfer of CD4
+
 T 
cells, either alone or in combination with CD8
+
 cells. In contrast, there is no clear correlation 
between GVHD clinical manifestations in mice and any individual TCR. GVHD responses were 
observed in mice treated with both 2C and m33 TCR-transduced T cells and thus this immune 
reaction directed at the host does not appear to be related to TCR affinity for the model peptide 
SIY. The most severe GVHD clinical signs were exhibited in mice which received a combination 
treatment of CD8
+
 and CD4
+
 cells. Combined T cell transfer resulted in extensive superficial 
skin lesions in the ears and tail, head and neck skin scabs, hunched posture, weight loss, and 
gastrointestinal complications. These data further support a role for CD4
+
 T cells in the 
pathogenesis of GVHD, especially in this particular model, and implicates CD8
+
 cells in 
exacerbating this pathophysiology when transferred in combination with CD4
+
 cells.  
 
Activated 2C CD4
+
 T cells result in GVHD 
 Conventionally, CD4
+
 T cells recognize exogenous peptides presented in the context of 
MHC class II molecules on the surface of antigen presenting cells (APC). Through TCR gene 
transfer, it is possible to redirect CD4
+
 cells to recognize peptides presented by MHC class I 
molecules. To explore adoptive immunotherapy with tumor antigen-specific CD4
+
 T cells, MHC 
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class I-restricted TCRs were introduced into activated, primary CD4
+
 cells. T cells were mock 
transduced, transduced with wild type affinity 2C TCR (Kd = 30 μM) or transduced with the high 
affinity m33 TCR (Kd = 30 nM). As a tumor model, Rag1
-/-
 mice were implanted subcutaneously 
(s.c.) with B16-SIY melanoma cells on the right flank. Once tumors became established, mice 
were administered 2C or m33 transduced CD4
+ 
T cells intravenously.  
Mice treated with saline or mock-transduced CD4
+
 T cells showed uniformly rapid tumor 
growth (Fig. 4.1a), with an overall survival of two weeks. Treatment with both the 2C and m33-
transduced CD4
+
 T cell populations mediated an initial rapid reduction in tumor growth resulting 
in delayed tumor progression and enhanced survival. Although the 2C-transduced CD4
+
 
population was capable of mediating significant tumor growth control, it could not prevent tumor 
recurrence and all 2C-treated mice ultimately succumbed to melanoma tumors. Over 25 day post 
T cell transfer, two 2C-treated mice began to display physical signs of GVHD believed to be 
induced by the transferred T cells (Fig. 4.1b). GVHD presentation included weight loss, 
ulceration and skin lesions associated with limbs, tails, ears and face of both mice. As a result of 
these symptoms, mice were euthanized and ear tissue harvested to assess T cell infiltration. 
Tissue sections from each mouse were incubated with anti CD3 antibody in order to detect 
presence of CD3
+
 lymphocytes. Staining of the ears revealed an abnormal abundance of 
lymphocytes dispersed throughout the ear dermis of Rag1
-/-
 mice 1239 and 1247 (Fig. 4.1c). 
 
CD4
+
 T cell responses following tumor cell rechallenge 
The most effective T cells at controlling tumor progression were the high-affinity m33 
CD4
+
 cells. Unlike adoptive transfer of 2C CD4
+
 cells, m33 CD4
+
 treatment resulted in tumor 
rejection and prolonged survival for over 60 days post T cell transfer in two of the mice (Fig. 
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4.2a). Availability of long-term survivor mice provided us with the opportunity to investigate in 
vivo T cell persistence and prolonged immune response against B16-SIY melanoma cells. Long-
term survivor mouse 1237 was rechallenged with B16-SIY cells. Prolonged memory anti-tumor 
activity in this mouse resulted in complete arrestment of tumor growth without additional 
adoptive transfer of T cells.  
Even though no physical GVHD signs were noted prior to tumor cell rechallenge, mouse 
1237 developed scabs on both ears (Fig. 4.2b). Additionally, vitiligo in the area lateral to the 
right eye and in the area medial to both ears was observed and an open ulcer was present 
anteriorly, expanding laterally across the chest. With the purpose of detecting T lymphocytes, ear 
tissue was harvested and labeled with anti CD3 antibody and DAPI as a counterstain. 
Immunohistochemistry showed ear tissue from mouse 1237 greatly infiltrated by CD3 positive T 
cells (Fig. 4.2c). CD3 staining revealed extensive infiltration of T cells throughout the ear similar 
to the T cell infiltration observed in ears from 2C CD4
+
 treated mice. These results suggest 
presence of reactive donor T cells following tumor cell rechallenge with B16-SIY.  
In addition to ear tissue, we histologically examined stomach, intestine, liver and lung 
tissue from mouse 1237 and an untreated control mouse for comparison. All of the tissue was 
paraffin embedded, sectioned and hematoxylin and eosin-stained for assessment of pathology. 
Histopathological changes consistent with GVHD were evident in tissues from mouse 1237. 
Abnormal histological findings included a large lymphoid follicle in the lung, perivascular 
lymphoid cuffing in the liver, a focal area of neutrophilic inflammation in the stomach, and a 
mild lymphoid infiltrate in the villi of the small intestine (Fig. 4.3). These findings combined 
with clinical signs and CD3
+
 cell infiltration in the dermis are strongly characteristic of GVHD 
pathology, which is predominately characterized by damage to the liver, skin and the 
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gastrointestinal tract [15]. The GVHD development is likely mediated by the initial adoptive 
transfer of antigen-specific CD4
+
 lymphocytes. It is noteworthy that GVHD pathology 
development was delayed over 65 days post initial T cell transfer and only became physically 
discernible following B16-SIY tumor cell rechallenge. 
 
GVHD induced by combined adoptive transfer of TCR- transduced CD8
+
 and CD4
+
 cells 
GVHD reactions were not melanoma-specific as these were also observed with adoptive 
T cell transfer for glioma immunotherapy. We performed experiments to investigate the role of 
CD4
+
 helper T cells transduced with high affinity TCRs in enhancing the antitumor immune 
function of CD8
+
 cytotoxic T lymphocytes (CTLs) in a glioma brain tumor model. We 
transduced both CD8
+
 and CD4
+
 primary murine T cells with gene modified TCRs and assessed 
their functional activity in vivo. Specifically, we examined the effects of TCR-modified T cells 
on survival of glioma tumor-bearing mice.  
Primary polyclonal murine CD8
+
 and CD4
+
 T cells were isolated from C57BL/6 mice 
splenocytes and activated with anti-CD3/anti-CD28 coated beads as performed for all studies 
previously discussed. Next, T cells were mock-transduced or transduced with retroviral 
supernatant containing the wild-type 2C TCR or the high affinity m33 TCR. Flow cytometry 
analysis of CD8
+
 and CD4
+
 T cells 3 days post-transduction was performed to assess the 
expression of 2C and m33 TCR, respectively. T cell labeling with anti CD8α and anti Vβ8.1/8.2 
antibodies confirmed successful CD8
+
 T cell isolation and 2C TCR transduction efficiency with 
88% CD8
+Vβ+ T cells present in the T cell population (Fig. 4.4a). CD4+ T cell isolation and m33 
TCR expression was verified with anti CD4 and anti Vβ8.1/8.2 antibodies showing a 64% TCR 
transduction efficiency of the CD4
+ 
T cell population (Fig. 4.4b). Mock-transduced T cells also 
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include Vβ positive cells (16-20%) which represent endogenous TCRs expressed by polyclonal T 
cells.  
To assess the anti-tumor activity of transduced CD8
+
 and CD4
+ 
T cells, a pilot 
experiment was performed with GL261-SIY tumor cells implanted intracranially into a small 
sample of RAG1
-/-
 mice (Fig. 4.4c). Thirteen days post-tumor cell infusion, mice received saline, 
as control, or TCR-transduced T cells intravenously. Similar to saline controls (median survival: 
24 days), mock CD4
+
 (median survival: 26 days) treated mice succumbed to GL261-SIY brain 
tumors within 1 month post glioma tumor cell implant. Surprisingly, administration of CD4
+
 T 
cells transduced with the high affinity TCR m33 did not inhibit tumor growth (median survival 
31 days). Unlike the survival benefit observed with 2C CD4
+
 T cell treatment for melanoma, 
m33 CD4
+
 cells did not provide a survival advantage against established glioma brain tumors.  
Conversely, a survival benefit resulted with adoptive transfer of mock CD8
+
, 2C CD8
+
, 
or the combination of 2C CD8
+
 and m33 CD4
+ 
T cells. Survival time was extended with 2C 
CD8
+
 T cell treatment, consistent with previous results observed against 10 day old glioma 
tumors. Mock-transduced CD8
+
 cells also extended survival of all treated mice with two mice 
surviving over 80 days post tumor cell infusion. These T cells express endogenous TCRs with 
specificity for a variety of peptides. Most importantly, these cells may include tumor-reactive T 
cells which can respond to tumors and suppress tumor progression [16]. Thus, suppression of 
GL261-SIY tumor growth by mock CD8
+
 cells may be a result of SIY/K
b
 reactive T cells present 
in the isolated polyclonal CD8
+
 T cell population from C57BL/6 splenocytes. In other survival 
experiments, some tumor growth control has been observed with mock CD8
+
 T cell treatment.   
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Such robust prolonged survival was also achieved with adoptive transfer of combined 2C 
CD8
+
 and m33 CD4
+ 
T cells. In comparison to saline control, survival time was significantly 
extended with combined CD8
+
/CD4
+
 treated mice surviving over 60 days post tumor cell 
implant. These findings suggest that primary CD4
+
 T cells transduced with high affinity TCRs 
may affect the effector functions of CD8
+
 CTLs.  
Co-transfer of TCR transduced CD8
+
 and CD4
+
 T cells into GL261-SIY tumor-bearing mice 
results in GVHD pathology 
Although our primary goal focused on investigating the effects of combining antigen-
specific CD8
+
 and CD4
+ 
T cells for adoptive therapy, the survival benefit mediated by this T cell 
treatment combination resulted in severe GVHD clinical signs. These signs were more robust 
than those observed with the melanoma model. Firstly, the initial GVHD signs (skin and tail 
scabs/lesions) appeared earlier in the glioma brain model compared to the melanoma s.c. model. 
Secondly, GVHD physical signs were noted on mice that received combined 2C CD8
+
 and m33 
CD4
+
 T cell treatment yet not observed with one T cell type treatments (CD8
+
 or CD4
+
 only), 
such as with mock CD8
+
 or 2C CD8
+
 T cells which were treatments that also resulted in a 
prolonged survival of mice.  
Mice 1355 and 1414 both received combined 2C CD8
+
 and m33 CD4
+
 T cells. Following 
T cell transfer, they displayed ear scabs, skin irritation, head and neck scabs, as well as peeling 
and redness on their tails. To further examine whether additional host tissue injury was induced 
by the transferred T cells, intestine, liver, lung and stomach were harvested, hematoxylin & 
eosin-stained, and examined for GVHD associated immunopathology. Histopathologic analysis 
of intestine, liver, and lung tissue, but not stomach tissue, revealed sloughing, microabscessation, 
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neutrophilic inflammation, and prominent lymphocytic infiltration compatible with GVHD (Fig. 
4.5). Besides intestinal, liver and lung infiltration by lymphocytes and neutrophils, effector 
lymphocytes mediated GVHD in the skin of mice 1355 and 1414. Skin tissue from the tail and 
ear was harvested from these mice 66 days following glioma brain tumor cell infusion. Tissue 
histopathology demonstrated diffuse lymphocytes present at the interface of the dermis and 
epidermis on the skin surface and associated with hair follicles (Fig. 4.6). Additionally, 
significant numbers of neutrophils were noted infiltrating ulcerated areas of the epidermis. The 
exacerbated pathophysiology involved with combined CD8
+
/CD4
+
 T cells suggests greater 
induction of GVHD-associated T cells with adoptive therapy utilizing this particular T cell 
combination resulting in immune-mediated tissue injury and inflammation. These results validate 
an important factor affecting the severity of GVHD development: type of T cell subset (CD8
+
 or 
CD4
+
; alone or in combination) transferred into tumor-bearing recipient mice.  
 
4.4 Discussion 
 
Several strategies have been proposed to prevent or reduce TCR gene therapy-induced 
GVHD. TCR mispairing can be a source of TCRs with unknown specificities for host tissue and 
lead to GVHD development [17,18]. Through the incorporation of an additional disulfide bond 
within the constant region of the exogenous TCR, it is possible to reduce pairing of exogenous 
TCR chains with endogenous TCR chains [19-21]. Indeed, the TCR constructs used in all studies 
described here have cysteines added to facilitate disulfide bonds between the TCR constant 
chains [22]. Of note, this approach may reduce the levels of TCR mispairing but it is possible it 
may not completely eliminate all TCR mispairing. An alternative method involves the use of 
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single chain VαVβ T cell receptors (scTv) instead of full length heterodimeric TCRs [23]. As 
illustrated by Aggen et al., scTvs are capable of mediating functional T cell activity while 
completely avoiding TCR mispairing. High affinity single chain TCRs (VαVβ) introduced into 
CD8
+
 or CD4
+
 T cells and adoptively transferred into mice implanted with s.c. B16-SIY tumors 
successfully enhanced survival without noted GVHD in one experiment (n=2/group, data not 
shown). Mispairing could also be reduced by introducing small-interfering RNA (siRNA) to 
specifically target endogenous TCRs in conjunction with an introduced TCR resistant to siRNA 
[24,25]. 
Even with strategies implemented to reduce mispairing, GVHD may develop in mice 
following TCR gene therapy. As with inflammatory syndromes, GVHD is typically diagnosed 
after onset of clinical symptoms. As a result, it is imperative to generate strategies which can 
reverse or lessen GVHD pathology. Incorporating suicide genes into donor T cells allows for 
depletion of transferred lymphocytes in the event that graft-versus-host responses occur. There is 
a body of evidence supporting the feasibility of transducing suicide transgene into donor 
lymphocytes with improved GVHD following depletion of the targeted T cells [26-29]. It is also 
viable to control adoptively transferred T cells by introducing protein-coupled TCRs which can 
be eliminated with administration of protein-specific depleting antibodies [30].  
Suppression of T cell mediated immune pathology can be achieved by transferring 
CD4
+
CD25
+
 regulatory T cells (Tregs) [31-33]. Work with inflammatory bowel disease murine 
models, such as ulcerative colitis, has successfully demonstrated the feasibility of transferred 
Tregs to cure established pathology [34]. Likewise, it is possible to employ Tregs to reverse or 
reduce T cell mediated GVHD pathology. The therapeutic potential of human Tregs has been 
demonstrated through ex vivo expansion of human Foxp3
+
 Tregs [35,36]. Expanded human 
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Tregs maintain their suppressive phenotype and are capable of reducing GVHD signs in NOD-
SCID mice. Transfer of antigen-specific Tregs has also been investigated with positive results. 
Although polyclonal Tregs can be effective at controlling GVHD, antigen-specific Tregs show 
superior disease suppression. Antigen-specific Tregs can be derived from isolated, antigen-
specific T cells which can then be transduced with Foxp3 [37,38]. However, it is challenging to 
isolate and expand adequate numbers of antigen-specific Tregs. To bypass this limitation, Tregs 
can be dual transduced with Foxp3 and an antigen-specific TCR. As demonstrated by Wright and 
colleagues, redirected Tregs retain their suppressive activity and effectively reduce inflammation 
in an arthritis model [38]. 
 Similarly, in future studies we will explore strategies to optimally reduce and prevent 
GVHD development following T cell therapy. Ongoing experiments aim to determine whether 
cellular therapy with Tregs can prevent progression of established GVHD in RAG1
-/-
 mice 
treated with combined 2C CD8
+
/m33 CD4
+
 T cells. It is important to determine the ideal timing 
for Treg transfer and the optimal number of Treg cells that should be administered to achieve the 
desired results. Furthermore, transfer of antigen-specific Tregs will be assessed with TCR 
transduced cells in the s.c. melanoma tumor model. In summary, these results clearly show 
GVHD development in recipient mice following transfer of activated TCR-transduced T cells. 
However, to date, similar immune-mediated responses have not been reported in humans. 
Through our understanding of the mechanisms involved in inducing GVHD, we will improve the 
outcome of TCR gene-modified T cell therapy while maintaining effective antitumor responses.  
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